Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell

Subclass of:

435 - Chemistry: molecular biology and microbiology

435440000 - PROCESS OF MUTATION, CELL FUSION, OR GENETIC MODIFICATION

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435456000 The polynucleotide is encapsidated within a virus or viral coat 52
435462000 Involving site-specific recombination (e.g., Cre-lox, etc.) 22
435463000 Involving general or homologous recombination (e.g., gene targeting, etc.) 19
435461000 Involving electroporation 18
435465000 Involving co-transfection 13
435467000 Introducing an oncogene to establish a cell line 5
20130029424METHOD FOR THE GENERATION OF MONOCLONAL ANTIBODIES DERIVED FROM HUMAN B CELLS - The present invention relates, in general, to human B cells, and, in particular to a method of immortalizing and cloning human B cells and to monoclonal antibodies derived therefrom. The invention further relates to methods of using the monoclonal antibodies for therapeutic and diagnostic purposes.01-31-2013
20120238023Novel Method for Producing Differentiated Cells - The present invention has an object of providing a method for producing specific cells by amplifying cells in a desired differentiation stage. The present invention provides a method for producing specific cells by inducing differentiation of cells, wherein an oncogene is forcibly expressed in cells in a desired differentiation stage to amplify the cells in the desired differentiation stage. The present invention also provides a method for producing specific cells, wherein oncogene-induced senescence (OIS) which is induced by the oncogene expressed in the cells in the desired differentiation stage is suppressed.09-20-2012
20110223670ETS2 AND MESP1 GENERATE CARDIAC PROGENITORS FROM FIBROBLASTS - A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mesp1.09-15-2011
20120214243METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS - Provided are a method of improving iPS cell establishment efficiency, comprising the step of transferring Lin28B or a nucleic acid that encodes Lin28B to a somatic cell, particularly to a somatic cell on which Lin28 is ineffective or less effective than Lin28B in improving iPS cell establishment efficiency, and a method of producing an iPS cell, comprising the step of transferring Lin28B or a nucleic acid that encodes Lin28B and a nuclear reprogramming substance to a somatic cell. Also provided are an iPS cell comprising a nucleic acid that encodes Lin28B, that can be obtained by the method of producing an iPS cell, and a method of somatic cell production by forcing the iPS cell to differentiate into a somatic cell.08-23-2012
20090275139MATERIALS AND METHODS RELATING TO THE PRODUCTION AND MAINTENANCE OF CELL LINES - The invention provides methods for maintaining cell lines from primary cells, i.e., non-transformed cells, using expression of the signal transducer of activation and transcription (STAT). The methods are particularly suitable for maintenance of B-cells.11-05-2009
435459000 Involving particle-mediated transfection (i.e., biolistic transfection) 5
20090233367Method of Transferring Substance Into Cell - There is provided a method by which multiple types of substances desired to be transferred into cells can be continuously transferred into multiple types of cells by a convenient procedure, a cell in which the substance desired to be transferred into cells has been taken up by this method, and an apparatus for transferring a substance into cells by this method. The foregoing objects can be achieved by electrospraying cells with a liquid free from the substance to be transferred into cells while the cells are kept in contact with the substance to be transferred into cells, or first electrospraying cells with a liquid free from the substance to be transferred into cells and then bringing the cells into contact with the substance to be transferred into cells.09-17-2009
20090068745COMPOSITIONS AND METHODS FOR PERFORMING REVERSE GENE THERAPY - The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.03-12-2009
20090130762Activation of HCV-specific T cells - The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD405-21-2009
20120135526LOW-PRESSURE BIOLISTIC BARRELS - Low pressure biolistic barrels and biolistic devices including the same are provided. Aspects of the biolistic barrels include the presence of one or more pressure-reducing elements. Also provided are kits which include the biolistic barrels, as well as methods of delivering a molecule to a target site with the biolistic barrels and devices that include the same. The devices and methods described herein find use in a variety of applications, including in vivo and in vitro high-precision delivery applications.05-31-2012
20090098653Transgenomic Mitochondria, Transmitochondrial Cells and Organisms, and Methods of Making and Using - The invention provides transgenomic mitochondria, transmitochondrial cells and organisms, and the materials and methods for making such mitochondria, cells, and organisms.04-16-2009
435458000 The polynucleotide is coated with or encapsulated within a lipid containing material (e.g., liposome, etc.) 3
20100041152METHODS FOR ENCAPSULATING PLASMIDS IN LIPID BILAYERS - Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.02-18-2010
20130065308CATIONIC LIPIDS - The invention provides a cationic lipid comprising: 03-14-2013
20090233366COMPOSITION FOR INTRODUCTION OF NUCLEIC ACID - Composition with weak cytotoxicity for introducing a nucleic acid, such as a short oligonucleotide or a gene, into a cell for expression of the gene in the cell. The composition includes a lipid and a compound represented by a formula (I):09-17-2009
435464000 Involving gene duplication within the cell (e.g., amplification, co-amplification, etc.) 1
20120064631METHOD FOR AMPLIFICATION AND HIGH-LEVEL EXPRESSION OF TARGET GENE IN MAMMALIAN CELL, AND KIT FOR ACHIEVING THE METHOD - The present invention provides novel means for amplifying a target gene outside a chromosome of the mammalian cell with a high probability in amplifying a target gene with use of IR/MAR plasmid, to further improve a high-level gene amplification system. The present invention is a method of amplifying a target gene outside a chromosome of a mammalian cell, and includes the step of transferring, concurrently to a mammalian cell, (i) a vector including (a) a mammalian replication initiation region functioning in a mammalian cell and (b) a nuclear matrix attachment region functioning in a mammalian cell, (ii) a target gene, and (iii) a polynucleotide including a telomere repetitive sequence.03-15-2012
Entries
DocumentTitleDate
20130045538MODIFIED U7 SNRNAS FOR TREATMENT OF NEUROMUSCULAR DISEASES - The present invention relates to a method to improve the activity of engineered U7 snRNAs used in the context of RNA-based therapeutics; particularly in exon skipping, exon inclusion, and mRNA eradication strategies. The resulting modified snRNAs are useful for treating neuromuscular diseases, in particular Duchenne neuromuscular dystrophy, myotonic dystrophy DM1 and spinal muscular atrophy.02-21-2013
20130045537METHODS AND COMPOSITIONS RELATING TO MULTICILIATE CELL DIFFERENTIATION - Compositions and methods relating to development of multiciliate cells are provided.02-21-2013
20120171771MODIFIED IPS CELLS HAVING A MUTANT FORM OF A HUMAN IMMUNODEFICIENCY VIRUS (HIV) CELLULAR ENTRY GENE - Methods and composition for generation of genetically modified induced pluripotent stem cells and hematopoietic cell derived therefrom are provided. For example, in certain aspects those cells comprise a modified gene structure related to HIV cellular entry, such as CCR5 mutants.07-05-2012
20120171770BIOENGINEERED SILK PROTEIN-BASED NUCLEIC ACID DELIVERY SYSTEMS - Nucleic acid transfer is achieved using a silk-based delivery system which releases nucleic acids from silk-based complexes. The silk-based complexes, which are composed, for example, of plasmid DNA (pDNA) and recombinant silk containing polycation and specific polypeptides sequences, can show high biocompatibility, high delivery efficiency, cell selectivity and controlled release of nucleic acid for nucleic acid transfection.07-05-2012
20100075422TRANSFECTION MICROARRAYS - A transfection method of introducing sample molecules into cells is provided, comprising: 03-25-2010
20100075421Efficient method for nuclear reprogramming - A method of preparing induced pluripotent stem cells, comprising a nuclear reprogramming step with a nuclear reprogramming factor in the presence of miRNA, wherein said miRNA has a property of providing a higher nuclear reprogramming efficiency in the presence of said miRNA than in the absence thereof.03-25-2010
20100075423METHODS AND COMPOSITIONS RELATING TO POLYPEPTIDES WITH RNASE III DOMAINS THAT MEDIATE RNA INTERFERENCE - The present invention concerns methods and compositions involving RNase III and polypeptides containing RNase III domains to generate RNA capable of triggering RNA-mediated interference (RNAi) in a cell. In some embodiments, the RNase III is from a prokaryote. RNase III activity will cleave a double-stranded RNA molecule into short RNA molecules that may trigger or mediate RNAi (siRNA). Compositions of the invention include kits that include an RNase III domain-containing polypeptide. The present invention further concerns methods using polypeptides with RNase III activity for generating RNA molecules that effect RNAi, including the generation of a number of RNA molecules to the same target.03-25-2010
20130034907BIOLOGICAL CIRCUIT CHEMOTACTIC CONVERTERS - Described herein are novel biological circuit chemotactic converter that utilize modular components, such as genetic toggle switches and single invertase memory modules (SIMMs), for detecting and converting external inputs, such as chemoattractants, into outputs that allow for autonomous chemotaxis in cellular systems. Flexibility in these biological circuit chemotactic converter is provided by combining individual modular components, i.e., SIMMs and genetic toggle switches, together. These biological converter switches can be combined in a variety of network topologies to create network systems that regulate chemotactic responses based on the combination and nature of input signals received.02-07-2013
20090162935VACCINIA VIRUS HOST RANGE GENES TO INCREASE THE TITER OF AVIPOXVIRUSES - The invention concerns an Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene. The invention further relates to cells, preferably avian cells, comprising a Vaccinia virus host range gene or a homologue of said host range gene. Moreover, the invention concerns the use of a Vaccinia virus host range gene or a homologue thereof to increase the titer of avipoxviruses produced from cells after infection of said cells with the avipoxvirus, wherein the host range gene is expressed in the cells.06-25-2009
20090170205METHOD OF MAINTENANCE AND EXPANSION OF HEMATOPOIETIC STEM CELLS - [Problem] Provided are a method of maintaining/expanding hematopoietic stem cells, a hematopoietic stem cell population obtained by the method, a hematopoietic function ameliorating agent based on administration of the hematopoietic stem cell population to a living organism, and the like.07-02-2009
20100105140PLAICE DNA TRANSPOSON SYSTEM - This document describes the Passport transposon system and methods of making and using the same.04-29-2010
20100105139Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents - A carrier system for the delivery of therapeutic and/or diagnostic agents is described. The carrier system is comprised of ligands and a biodegradable polycation for complexing polyanionic molecules such as RNAi, said polycation forming a coating on the outer surface of anionic or neutral liposomes. Also disclosed is a method for using the composition to deliver to target cells and enhance cell membrane penetration of therapeutic and/or diagnostic agents.04-29-2010
20100041151Compositions and methods for treating lysosomal storage disease - The present invention provides recombinant viral and non-viral vectors comprising a transgene encoding a biologically active human lysosomal enzyme that are able to infect and/or transfect and sustain expression of the biologically active human lysosomal enzyme transgene in mammalian cells deficient therein. In addition, methods are provided for providing a biologically active human lysosomal enzyme to cells deficient therein, which comprises introducing into the cells a vector comprising and expressing a transgene encoding the biologically active human lysosomal enzyme, wherein the vector is taken up by the cells, the transgene is expressed and biologically active enzyme is produced. The cells may be infected and/or transfected by the vector, dependent upon whether the vector is a viral vector and/or plasmid or the like. The invention also provides a method of supplying a biologically active human lysosomal enzyme to other distant cells deficient therein wherein the transfected and/or infected cells harboring the vector secrete the biologically active enzyme which is then taken up by the other deficient cells. In a preferred embodiment the present invention provides for sustained production of biologically human active α-galactosidase A in cells of Fabry individuals that are deficient in said enzyme.02-18-2010
20100144039Pluripotency determining factors and uses thereof - Pluripotency determining factors are described which act intracellularly and maintain a pluripotent cell in a pluripotent state in the absence of gp130 activation, which maintain or confer pluripotency of a human stem cell, which maintain or confer pluripotency of a mouse ES cell, and which maintain or confer pluripotency of a stem cell from a non-permissive strain of mice. The factors and vectors encoding or activating the factors are used to maintain and derive pluripotent cells, especially of higher mammals, including humans.06-10-2010
20090124012TOXIN/ANTITOXIN SYSTEMS AND METHODS FOR REGULATING CELLULAR GROWTH, METABOLIC ENGINEERING AND PRODUCTION OF RECOMBINANT PROTEINS - The present invention provides compositions and method for regulating cellular growth and metabolism, intra- and extracellular enzymatic activities, and synthesis of endogenous and/or heterologous proteins, comprising the steps of cloning genes encoding an mRNA interferase (toxin) and its cognate antitoxin; expressing these proteins in a host cell from two separate constitutive or inducible promoters on one or more plasmid vectors or on a chromosome; and regulating the cellular growth and metabolism by controlling the ratio of toxin and antitoxin present in the host cell. Optionally, the method provides further steps of modifying an endogenous or heterologous gene of interest to substitute all mRNA recognition sequences with sequences that are not cleavable by the mRNA interferase being expressed without any change in the amino acid sequence of the protein encoded by the gene; and co-expressing the gene of interest in the same host cell.05-14-2009
20090042298COMPOSITIONS AND METHODS FOR ENHANCING DELIVERY OF NUCLEIC ACIDS INTO CELLS AND FOR MODIFYING EXPRESSION OF TARGET GENES IN CELLS - Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells. The transported nucleic acids are active in target cells as small inhibitory nucleic acids (siNAs) that modulate expression of target genes, mediated at least in part by RNA interference (RNAi). The siNA/polypeptide compositions and methods of the invention provide effective tools to modulate gene expression and alter phenotype in mammalian cells, including by altering phenotype in a manner that eliminates disease symptoms or alters disease potential in targeted cells or subject individuals to which the siNA/polypeptide compositions are administered.02-12-2009
20090042296TRANSFECTION READY EUKARYOTIC CELLS - Described herein are frozen populations of transfection ready competent eukaryotic cells, transfection kits comprising the frozen populations of transfection ready competent cells, and methods of using the same.02-12-2009
20090305420SRSV DETECTION KIT - This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related virus constituting peptides selected from the following peptide groups (a) to (k), respectively: (a) a peptide having an amino acid sequence represented by SEQ ID NO: 1, and the like, (b) a peptide having an amino acid sequence represented by SEQ ID NO: 2, and the like, (c) a peptide having an amino acid sequence represented by SEQ ID NO: 3, and the like, (d) a peptide having an amino acid sequence represented by SEQ ID NO: 4, and the like, (e) a peptide having an amino acid sequence represented by SEQ ID NO: 5, and the like, (f) a peptide having an amino acid sequence represented by SEQ ID NO: 6, and the like, (g) a peptide having an amino acid sequence represented by SEQ ID NO: 7, and the like, (h) a peptide having an amino acid sequence represented by SEQ ID NO: 8, and the like, (i) a peptide having an amino acid sequence represented by SEQ ID NO: 9, and the like, (j) a peptide having an amino acid sequence represented by SEQ ID NO: 10, and the like, and (k) a peptide having an amino acid sequence represented by SEQ ID NO: 11, and the like.12-10-2009
20090305419Compositions for linking DNA-binding domains and cleavage domains - Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.12-10-2009
20090305418CELL THERAPY METHOD FOR THE TREATMENT OF TUMORS - T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; 12-10-2009
20130059386INDUCED PLURIPOTENT STEM CELLS PRODUCED WITH OCT3/4, KLF AND SOX - The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.03-07-2013
20130059385METHODS OF GENERATING PLURIPOTENT STEM CELLS - Disclosed are methods, compositions, and kits of producing an induced pluripotent stem cell from a mammalian non-pluripotent cell that does not endogenously or heterologously express Sox2 and is not in contact with a Sox2 polypeptide.03-07-2013
20120309091Methods And Compositions For Gene Inactivation - Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.12-06-2012
20090280568S100B mini-promoters - Isolated polynucleotides comprising an S100B promoter are provided, where an S100B regulatory element is operably joined to an S100B basal promoter utilizing a non-native spacing between the promoter and regulatory elements. The promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.11-12-2009
20090197336SUPPRESSION OF POLYMORPHIC ALLELES - Methods and agents for suppressing expression of a mutant allele of a gene having a polymorphism are provided. The methods of the invention provide suppression effectors such as antisense nucleic acids or ribozymes, that bind to nucleic acid regions having a polymorphism within a gene such that one allele of a gene is exclusively or preferentially suppressed. The method also provides the administration of a replacement nucleic acid, if required. The invention has the advantage that the same suppression strategy, when directed to polymorphisms, could be used to suppress, in principle, many mutations in a polymorphic gene. This is particularly relevant when large numbers of mutations within a single gene cause disease pathology.08-06-2009
20090233365ARGININE-CONJUGATED BIOREDUCIBLE POLY(DISULFIDE AMINE) POLYMERS FOR GENE DELIVERY SYSTEMS - An arginine-grafted bioreducible poly(disulfide amine) (“ABP”) as a reagent for efficient and nontoxic gene delivery is described. ABP forms positively charged nano-particles of less than 200 nm with plasmid DNA. ABP is biodegraded under reducing conditions, such as the cytoplasm. ABP exhibits much higher transfection efficiency than polyethyleneimine in mammalian cells and exhibits no cytotoxicity.09-17-2009
20090047741Compositions and methods comprising a ligand of chemerin R - The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.02-19-2009
20120238022INDUCIBLE SYSTEMS AND METHODS FOR CONTROLLING siRNA EXPRESSION - An inducible system and methods for controlling expression of siRNA are provided. An inducible system for producing siRNA only in the presence of HIV TAT, and methods for inhibiting HIV-1 gene expression in cells comprising such inducible system also are provided.09-20-2012
20090130760METHOD FOR THE UBIQUITINATION OF COMMON SUBUNIT OF RNA POLYMERASES - The present invention provides a method for ubiquitinating RNA polymerases, comprising bringing the RNA polymerases into contact with BRCA1-BARD1.05-21-2009
20100003755Methods for identifying genomic deletions - The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.01-07-2010
20080274548DOPOMINERGIC NEURONS DIFFERENTIATED FROM EMBRYONIC CELLS FOR TREATING NEURODEGENERATIVE DISEASES - Disclosed herein are methods for generating dopaminergic neurons in vitro by inhibiting a pathway component of a TGF-β signaling pathway and overexpressing one or more cell fate-inducing polypeptides in pluripotent cells, causing differentiation of the pluripotent cells into dopaminergic neurons. Also disclosed are methods for treating a neurodegenerative disease in a patient by generating dopaminergic neurons in vitro, and transplanting them into the brain of the patient, such that the dopaminergic neurons are sufficient to reduce or eliminate the symptoms of the neurodegenerative disease.11-06-2008
20110045591Controlled Activation of Non-LTR Retrotransposons in Mammals - The invention relates to nucleic acids, vector constructs which allow the controlled activation and inhibition of retrotransposition of non-LTR retrotransposons. The methods of this invention are useful for preparing said nucleic acids and vector constructs and introducing them into cells.02-24-2011
20100003756Methods and compositions for generation of Bax-and Bak-deficient cell lines - Disclosed herein are methods and compositions for generation of Bak- and/or Bax-deficient cell lines using engineered nucleases.01-07-2010
20110008894LYOPHILIZED PLASMID/DNA TRANSFECTION REAGENT CARRIER COMPLEX - Disclosed is a novel formulation for the production of a lyophilized plasmid/DNA transfection reagent complex capable of serving as a carrier for additional free plasmids. Upon rehydration, this plasmid/DNA transfection reagent carrier can be used to introduce simultaneously the complexed plasmid and the additional free plasmids into animal cells. This novel formulation can be useful for viral particle production, gene transfer experiments like gene silencing experiments, reporter gene, or integration/selection experiments.01-13-2011
20100330676EXPRESSION OF SURROGATE LIGHT CHAINS - The present invention concerns surrogate light chain (SURROBODY™) constructs comprising surrogate light chain sequences with heterologous signal sequences.12-30-2010
20090042297Piggybac transposon-based vectors and methods of nucleic acid integration - Disclosed herein are compositions comprising integrating enzymes that can deliver nucleic acids to a target DNA. Additionally, the methods of using the compositions disclosed herein relate to treatments for a variety of infections, conditions, and genetic disorders.02-12-2009
20110287547NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS - Complexes comprising a cationic polymer, a nucleic acid and a metal ion are provided. In some embodiments, a complex may be used as a means for delivering nucleic acid to a cell. In some embodiments, a complex may be used as part of a gene therapy. Methods of making a complex comprising a cationic polymer, a nucleic acid, and a metal ion are also described. Methods of condensing a polyplex comprising a cationic polymer and a nucleic acid are also provided.11-24-2011
20110287546Automated intracellular manipulation and transfection - A method and apparatus whereby prokaryotic, eukaryotic and/or mammalian cells may have genetic agents inserted or removed or transferred in an automated and semi-quantitative fashion. The functional unit of the invention is composed of two rectangular plates: a contact plate with circular holes and a carefully aligned base plate with a pleurality of rods, which protrude through the center of the holes of the contact plate. The edges of the two plates are sealed lengthwise to create a space whereby fluid may flow through the proximal and distal openings to induce a negative pressure, vacuum suction, venturi effect at each hole of the contact plate. The rods and base plate may be coated with an electronically magnetizable surface which may attract and hold or repulse and release any magnetically responsive genetic agents.11-24-2011
20110294218CD34-DERIVED RECOMBINANT ADENO-ASSOCIATED VECTORS FOR STEM CELL TRANSDUCTION AND SYSTEMIC THERAPEUTIC GENE TRANSFER - Novel adeno-associated virus (AAV) isolates in nucleotide and amino acid forms and uses thereof are provided. The isolates show tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Discrete modified portions of the cap gene, VP1, VP2, and VP3, may be used alone or in combination in the present methods.12-01-2011
20100035345High Production System for Infectious Hepatitis C Virus Particle - The present invention relates to a method for producing infectious hepatitis C virus (HCV) particles, comprising a step of introducing an expression vector into a cell that allows HCV proliferation, such expression vector comprising: DNA sequences encoding the 5′ untranslated region, structural proteins, and, if necessary, non-structural proteins of HCV and DNA sequences encoding non-structural proteins and the 3′ untranslated region derived from the HCV JFH1 strain, which are located downstream of a polymerase I promoter; and a DNA fragment containing an RNA polymerase I terminator, which is located further downstream thereof.02-11-2010
20110217779Compositions and Methods for Non-Targeted Activation of Endogenous Genes - The present invention is directed generally to activating gene expression or causing over-expression of a gene by non-homologous or illegitimate recombination, of a regulatory sequence that causes expression of the gene. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.09-08-2011
20090098652SELF ASSEMBLING PEPTIDE SYSTEMS AND METHODS - The present invention provides a self-assembling peptide system which utilizes a bioactive sequence which enhances transfection efficiency. In particular, the present invention provides compositions and methods for transfecting aggregates of cells at a higher efficiency.04-16-2009
20090023215Novel reagents for transfection of eukaryotic cells - Compositions and methods for improved delivery of macromolecules into eukaryotic cells are provided. Fusogenic peptides from fusion proteins of non-enveloped viruses enhance the efficiency of transfection of eukaryotic cells mediated by transfection agents such as cationic lipids, polycationic polymers such as PEI and dendrimers. These fusogenic peptides are used as part of a transfection complex that efficiently delivers a macromolecule, for example, a nucleic acid, into a eukaryotic cell. Novel cationic lipids and compositions of cationic lipids also are provided that may be used for the introduction of macromolecules such as nucleic acids, proteins and peptides into a variety of cells and tissues. The lipids can be used alone, in combination with other lipids and/or in combination with fusogenic peptides to prepare transfection complexes.01-22-2009
20100112702Method designed to divert glucose away from the glycolytic pathway - A method to divert glucose away from glycolysis is described. The method is based on a planned “glucose sink” by introduction, into tumor cells, of nucleotide sequences from known genes whose products are comprised in lactose synthase enzymatic complex. The method is a process designed to correct, replenish or de novo induce lactose synthesis in cancer cells planned to be achieved by insertion of the cDNA of missing protein products capable of lactose synthesis by an expression vector under a strong promoter/enhancer. Intended introduction of the said enzyme expression system by a vector into the cancer cells is by transfection in culture for research. For therapeutic use introduction in vivo is intended by transvection/infection via nanotechnological delivery or viral delivery when delivery systems will be authorized. The best embodiment of this method is in medicine/veterinary where it may require a diagnostic step that defines in individual tumors, especially in mammary tumors, the quantitative and qualitative expression of endogenous genes that enable lactose synthesis, including mainly β4GalT1, α-lactalbumin, and galactose-generating glucose-epimerase, originating preferably from the same species in the case of human subjects. Expression deficiency, deletions, mutations or absence of one of these genes is a guide for induction, correction (if mutated) or replenishment.05-06-2010
20090148948NUCLEIC ACIDS ENCODING A G-PROTEIN COUPLED RECEPTOR INVOLVED IN TASTE TRANSDUCTION - The invention provides isolated nucleic acid and amino acid sequences of sensory cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sensory cell specific G-protein coupled receptors.06-11-2009
20090053812SCLERAL CELL STRAIN - The present invention provides a scleral cell strain capable of expressing an exogenous immortalizing gene, and a production method thereof. Since the scleral cell strain of the present invention can produce a sufficient number of cells and has constant and continuous proliferative capacity, it can be advantageously utilized for the elucidation of the pathogenesis of ophthalmic diseases such as scleral inflammation, and the development of a drug for the prophylaxis and/or treatment of said diseases. Moreover, the cell strain is not only highly useful for the biochemical-physiological studies of the sclera, and further for the study of cell differentiation mechanisms, but also possibly usable as a biological material of an artificial sclera.02-26-2009
20100120154METHOD FOR HOMOLOGOUS RECOMBINATION - The present invention discloses a method to construct eukaryotic cells having a target sequence in a chromosomal DNA sequence replaced by a replacement sequence of interest comprising: 05-13-2010
20100120153N-GLYCOSYLATION MUTANT OF MELANOMA DIFFERENTIATION ASSOCIATED GENE-7 - The present invention relates to MDA-7 variant proteins which are deficient in or lack glycosylation. It is based, at least in part, on the results of experiments which have demonstrated that such variants are functionally equivalent to wild-type MDA-7 protein. Such proteins may be more easily produced large-scale than the wild-type protein, and may be found to be less immunogenic (thereby facilitating treatment, especially repeated treatments). Accordingly, the present invention provides for such proteins (‘Gly(def)MDA-7 proteins’), nucleic acids encoding them (‘Gly(def)mda-7 nucleic acids), pharmaceutical compositions comprising such proteins or nucleic acids, and related methods of treatment.05-13-2010
20100120152Methods for expression of transgenes - The present invention relates to compositions and methods for increasing long term expression in vitro and in vivo, comprising sequences and gene expression cassettes that increase expression of genes to which they are operably linked.05-13-2010
20100087005AUXILIARY REAGENT FOR GENE TRANSFER - The present invention provides a means for introducing a gene of interest into a host cell with a higher degree of efficiency regardless of the gene transfer method employed and the type of the host cell. The auxiliary reagent for gene transfer of the present invention is characterized in that it comprises a peptide comprising a specific amino acid sequence represented by formula (I), a mutant or derivative thereof, or a salt of the peptide, the mutant or the derivative.04-08-2010
20120107937Mitochondrial enhancement of cells - Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.05-03-2012
20100081202PROCESS FOR FACILITATING NUCLEIC ACID TRANSFER - Means for transferring efficiently a desired nucleic acid into a cell is provided.04-01-2010
20090263899CELL MODIFICATION METHOD AND CELL MODIFICATION DEVICE - The present invention relates to a cell modification method for modifying human or mammal immune cells, especially effector cells outside the human or mammal body, wherein in a first step at least one encapsulated substance, preferably an active pharmaceutical ingredient, is introduced in and/or arranged on isolated human or mammal immune cells and wherein in a second step prior to or after the introduction of said at least one substance the cytotoxic effector function of the isolated immune cells is enhanced. The present invention also relates to a correspondingly modified human or mammal immune cell and to a cell modification device.10-22-2009
20090263900Linear donor constructs for targeted integration - Disclosed herein are linear donor molecules comprising homology arms of 50-750 base pairs (e.g., 50-100 base pairs) flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.10-22-2009
20090263901STABLE NEURAL STEM CELL LINES - A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.10-22-2009
20090142842CLEAVABLE MODIFICATIONS TO REDUCIBLE POLY(AMIDO ETHYLENIMINE)S TO ENHANCE NUCLEOTIDE DELIVERY - Improved poly(amido ethylenimine) copolymers for gene delivery are disclosed. One illustrative embodiment includes polyethylene glycol (PEG) covalently bonded to a branched poly(triethyenetetramine/cystamine bisacrylamide) copolymer (poly(TETA/CBA)). The polyethylene glycol can be linear or branched. Another illustrative embodiment includes an RGD peptide covalently bonded to the poly(TETA/CBA)-PEG conjugate. Still another illustrative embodiment includes a method of using these compositions for transfecting a cell with a nucleic acid.06-04-2009
20090142841Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors - Vectors capable of stably integrating a transgene in the genome of a non-dividing cell or of a slowly-dividing cell, said vector comprising or expressing at least one immortalization molecule and cells immortalized with said vectors.06-04-2009
20110201120METHOD FOR INTRODUCING GENE INTO CELL, AND COMPOSITION FOR USE IN THE METHOD - The present invention provides a method for transferring a gene into cells, which is practically useful and can achieve high transfer efficiency, and also a composition for use in the method. By bringing a mixture of a composition comprising a diallylamine sulfur dioxide copolymer having a repeating unit represented by the formula (1) or a salt thereof and a gene into contact with a cell, a gene such as DNA and RNA can be transferred into a target cell safely and conveniently, and into a cell at a specific site with high gene transfer efficiency.08-18-2011
20090275136Nuclear Targeting Sequence - The present provides nuclear localization signaling (NLS) sequences derived from titin, comprised of amino acids 181-220: SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR and fragments thereof, such as amino acids 193-208: VQGEEEVP AKKTKTIV; amino acids 199-208: VPAKKTKTIV; and amino acids 200-206: PAKKTKT. The NLS sequences can be linked to agents, such as peptides, proteins or nucleotides, for transporting the agents into the nucleus of cells, and the NLS-agent complex can be further linked to antibodies or ligands for specific binding to cells. Also provided is a method for constructing cDNAs comprising combining a NLS sequence with a nucleic acid sequence for a target protein for expression and entry of the target protein into the nucleus of cells, which then can perform specific functions therein.11-05-2009
20090258424Cellular Delivery of siRNA - The invention provides a method for delivering a nucleic acid to a cell using a targeting molecule that is bound non-covalently to the nucleic acid. Compositions and kits are also provided.10-15-2009
20120295355NUCLEIC ACID DELIVERY USING MODIFIED CHITOSANS - The present invention is directed to the delivery of nucleic acids in a non-viral vector to cells by positively charged chitosan derivatives, including but not limited to chitosan-arginine, chitosan-lysine and chitosan-histidine.11-22-2012
20110171733Bovine Immunodeficiency Virus (BIV) Based Vectors - BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.07-14-2011
20090142840DNA encoding anti-apoptotic protein and recombinant 30K protein - The present invention relates to DNAs encoding anti-apoptotic 30K proteins. More particularly, the present invention is directed to 30K protein genes and a recombinant proteins prepared by using novel anti-apoptotic gene obtained from silkworm. The present invention also provides anti-apoptotic health care food, pharmaceutical preparation, additive for cell culture medium, and food supplement.06-04-2009
20090093058CELL TRANSFECTION ARRAY FOR INTRODUCTION OF NUCLEIC ACID - The subject of the present invention is to provide a microarray for introducing nucleic acid, the microarray capable of introducing and expressing nucleic acid into cells simply by adding the nucleic acid onto a plate and the like, and then seeding the cells thereon and culturing them without adding a nucleic acid-introducing reagent or additives. The subject is achieved by preparing the microarray including atelocollagen, a gene-introducing agent and nucleic acid on a plate and the like for the introduction of nucleic acid. The nucleic acid can be introduced into a cell by seeding cells into which nucleic acids are introduced on the microarray and culturing them without the need of preparing a mixture of viral vectors, nucleic acids and a nucleic acid-introducing agent after culturing cells or the need of adding a nucleic acid-introducing agent and additives.04-09-2009
20090209036Method for Accelerating Somatic Mutations and use Thereof in Proteomics - The invention relates to a method of accelerating the induction of somatic mutations in vitro. The inventive method comprises the expression of at least one cDNA expressing a modified version of the AID gene in the cells to be mutated, in culture conditions and a medium that are suited thereto, said modified version resulting from an AID gene in which the three hydrophobic amino acids, leu189, phe193 and leu196, have been replaced by means of alanine mutations in each case. The invention can be used to induce mutations in Burkitt's lymphoma BL2. The invention can also be used to induce mutations in the immunoglobulin genes of immortalised antibody-producing cells, such as mouse hybridoma cells, human hybridoma cells or human B-cell lines immortalised by the Epstein-Barr virus (EBV).08-20-2009
20090104702Attenuated chimeric flavivirus bearing attenuated Japanese encephalitis virus gene as backbone - A nucleic acid molecule containing nucleotide sequences that encode the capsid protein, pre-membrane protein and non-structural protein of Japanese encephalitis virus, and a nucleotide sequence that encodes the envelop protein of a second flavivirus, wherein the nucleotide sequence(s) that encode(s) the pre-membrane protein and/or non-structural protein of Japanese encephalitis virus contain(s) nucleotide mutations that produce one or more amino acid mutations that attenuate the virus.04-23-2009
20090104703Nucleic Acids Encoding Proteins Involved in Sensory Transduction - The invention provides isolated nucleic acid and amino acid sequences of sensory cell specific polypeptides, antibodies to such polypeptides, methods of detecting such nucleic acids and polypeptides, and methods of screening for modulators of sensory cell specific polypeptides.04-23-2009
20090275137HIGH AFFINITY TCR PROTEINS AND METHODS - T cell receptors (TCRS) that have higher affinity for a ligand than wild type TCRs are provided. These high affinity TCRs are formed by mutagenizing a T cell receptor protein coding sequence to generate a variegated population of mutants of the T cell receptor protein coding sequence; transforming the T cell receptor mutant coding sequence into yeast cells; inducing expression of the T cell receptor mutant coding sequence on the surface of yeast cells; and selecting those cells expressing T cell receptor mutants that have higher affinity for the peptide/MHC ligand than the wild type T cell receptor protein. The high affinity TCRs can be used in place of an antibody or single chain antibody.11-05-2009
20090286319MICROINJECTION METHOD AND DEVICE - An object of the present invention is to provide a method for introducing a physiologically active substance such as a gene into a cell, which introduces a physiologically active substance such as any given gene into any given cell in a view under a microscope, while significantly reducing invasiveness to the cell, and a device used for the above method. The present invention provides a method for introducing a physiologically active substance into a cell, which comprises: allowing a physiologically active substance to attach around a needle having a diameter of 500 nm or less, provided that it is able to be inserted into a cell; and inserting the above-described needle into the cell; and a microinjection device for carrying out the aforementioned method.11-19-2009
20090291502GENE INJECTION APPARATUS AND GENE INJECTION METHOD - A gene injection apparatus for injecting a gene into a cell held on a substrate, includes a needle unit. The needle unit includes a fine needle to be inserted into the cell immersed in a culture medium in which the gene is dispersed, and a flexible support part configured to hold the fine needle, the flexible support part being flexing when the fine needle is pressed onto the substrate. The gene injection apparatus further includes a drive unit configured to push down the flexible support part toward the substrate, further from a position where a tip of the fine needle contacts the substrate.11-26-2009
20090170203METHODS FOR FEMALE MAMMALIAN SPERMATOGENESIS AND MALE MAMMALIAN OOGENESIS USING SYNTHETIC NANOBIOLOGY - Herein are disclosed methods for producing female sperm by incorporating a female's chromosomes into a sperm cell via mostly natural spermatogenesis processes. The methods include transplanting (altered) female stem cells or (altered) cloned germ cells into sterilized testes of a male. Diploid female stem/germ cells are altered in two ways—transdifferentiation to facilitate the expression of spermatogenesis factors (for example, using artificial chromosomes) and/or retrodifferentiation to increase pluripotency and imprinting erasures. The altered cells are transplanted into (artificial) male testes to develop into sperm, which are used to fertilize an egg of a second female, or an egg of the original female. Also disclosed herein are methods for producing male eggs by adding an extra X chromosome to an adult male's germ cells, and cultivating the germ cells in vitro.07-02-2009
20110207224IN VIVO PRODUCTION OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING - The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vitro with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.08-25-2011
20110207225Methods and Systems for Manipulating Particles Using a Fluidized Bed - The present invention comprises methods and systems for manipulation of media and particles, whether inert materials or biomaterials, such as cells in suspension cell culture. The methods and systems comprise use of an apparatus comprising a rotating chamber wherein the actions of the combined forces fluid flow force and centrifugal force form a fluidized bed within the rotating chamber.08-25-2011
20110201119ALPHAVIRUS PACKAGING CELL LINES - This invention provides alphavirus packaging cell lines useful for commercial production of recombinant alphavirus particles and structural protein expression cassettes for making the packaging cell lines.08-18-2011
20100129913POLIOMA VECTOR EXPRESSING LONG DOUBLE-STRANDED RNAS - Polyoma viral vector production cell line comprising a heterologous polynucleotide sequence that is capable of being transcribed into an RNA sequence that is capable of folding into double stranded RNA of at least 50 base pairs in length, methods of producing said cell line, uses thereof and recombinant polyoma viral vectors and nucleic acid sequences relating thereto.05-27-2010
20090170204Novel cosmetic designs and products using intronic RNA - The present invention relates to a method and composition for generating a non-naturally occurring intron and its components capable of being processed into small hairpin RNA (shRNA) and/or microRNA (miRNA) molecules by skin cells and thus inducing specific gene silencing effects on skin pigment-related genes and/or aging-causing genes in the cells. The gene silencing effects so obtained are not only useful for lightening and whitening skin colors but also useful for suppressing unwanted aging gene activities in skins.07-02-2009
20080305547Method for enhanced functional expression of cell receptors - The invention relates to methods for enhancing functional expression of receptor molecules in recombinant cells, preferably heterologous cells. In the method, a eukaryotic cell is transformed or transfected with all of the nucleic acid molecule which encodes the receptor, one which encodes a GEF, such as Ric-8A or Ric-8B, and one which encodes Gαolf. The resulting, recombinant cells are then contacted with an agent that stimulates the functional expression of the receptor. Preferably, the receptor is an odorant receptor, or “OR,” and the agent is a ligand for that OR.12-11-2008
20110207223METHODS OF GENERATING ALPHAVIRUS PARTICLES - Strategies for increasing the productivity of alphavirus packaging cell lines and of reducing the possibility that replication competent virus may be generated during large scale production of recombinant alphavirus particles.08-25-2011
20100144038Composition And Method For Increasing Efficiency Of Introduction Of Target Substance Into Cell - The present invention provides a method capable of improving the efficiency of introducing a target substance (e.g., DNA, polypeptides, sugars, or complexes thereof), which is difficult to introduce (particularly, transfect) into a cell in any circumstances. Particularly, the present invention provides a composition for increasing the efficiency of introducing a target substance into a cell, comprising (a) an actin acting substance. The present invention also provides a device and method using such a composition.06-10-2010
20090029471Microelectromechanical devices useful for manipulating cells or embryos, kits thereof, methods of making same, and methods of use thereof - The present invention relates generally to microelectromechanical systems (MEMS) devices for the manipulation of cells or groups of cells, such as oocytes, embryos, and sperm. In particular, the present invention relates to Cell Labeling MEMS devices (01-29-2009
20090186414Methods of Generating Cardiomyocytes and Cardiac Progenitors and Compositions - The present disclosure provides methods of inducing cardiomyogenesis in a stem cell or progenitor cell, or in a population of stem cells or progenitor cells; and methods for expansion of (increasing the numbers of) cardiac progenitors. Cell compositions are also provided.07-23-2009
20090286320SITE-SPECIFIC RECOMBINATION IN EUKARYOTES AND CONSTRUCTS USEFUL THEREFOR - Site-specific recombinases provide a means of efficiently manipulating chromosomal sequences in mammalian cells in culture and in mice. Embryonic stem cells containing recombinase nucleic acid constructs that were expressed in the male germline would simplify current protocols for producing mice bearing homologously recombined alleles that have been secondarily rearranged by a site-specific recombinase, five lines of transgenic mice containing a fusion gene consisting of the mouse protamine 11-19-2009
20090137045Pyridinium Cationic Lipids as Gene Transfer Agents - Pyridinium cationic lipids useful as non-viral gene delivery agents are disclosed. The agents are prepared by reaction of pyrylium salts with primary amines. Also disclosed are methods of trasfectind cells using the pyridinium cationic lipids as gene transfer agents.05-28-2009
20080318319Novel Method of Nucleic Acid Transfer - The present invention provides a method of nucleic acid transfer comprising the following steps (a) and (b): 12-25-2008
20100003758METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.01-07-2010
20090011509INTEGRASE FUSION PROTEINS AND THEIR USE WITH INTEGRATING GENE THERAPY - In a method of targeting intergration of a transgene comprising retrovirus-like DNA into a eukaryotic genome, the genome is cleared by an endonuclease and the transgene is introduced at the site of cleavage, wherein the endonuclease is specific to a site in an abundant rDNA locus and is fused to an integrase that mediates the introduction of the transgene. The fusion protein may be new.01-08-2009
20090325297METHOD FOR INHIBITING EXPRESSION OF A PROTEIN IN A HEPATOCYTE - A method of screening a candidate compound for susceptibility to biliary excretion by a hepatocyte transport protein. The method includes the steps of providing a culture of hepatocytes comprising a transport protein, the culture having at least one bile canaliculus; exposing a candidate compound to the culture; and determining an amount of candidate compound in the at least one bile canaliculus, the amount of candidate compound in the at least one bile canaliculus indicating the susceptibility of the candidate compound to biliary excretion by the transport protein. In some embodiments determining the amount of candidate compound in the bile canaliculus comprises inhibiting expression of the transport protein, measuring the amount of candidate compound in the bile canaliculus and comparing amounts of compound in the canalicules with and without inhibition of the transport protein. A difference in the amount of candidate compound in the canaliculus indicates susceptibility of the candidate compound to biliary excretion by the transport protein. In one embodiment, expression of the transport protein is inhibited through introduction of a RNA having a sequence corresponding to a coding strand of the gene encoding the transport protein into the hepatocyte. Optionally, the culture of hepatocytes is a long-term culture in a sandwich configuration. The method is particularly applicable to the screening of multiple candidate compounds in a single effort.12-31-2009
20090081792IMMUNE POTENTIATING COMPOSITIONS OF CANCER CELLS - A composition of matter is disclosed, comprising an immunostimulatory molecule and animal cells cultured in the presence of at least one interferon (IFN) for a time and under conditions sufficient to enhance the antigen presenting function of said cells. Also disclosed are immunopotentiating compositions and their use for treatment and/or prophylaxis of a disease or condition.03-26-2009
20110143441Methods of Reprogramming Animal Somatic Cells - This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.06-16-2011
20110229970DUAL-CHAMBER PERFUSION BIOREACTOR FOR ORTHOPEDIC TISSUE INTERFACES AND METHODS OF USE - The subject invention concerns a perfusion bioreactor device and methods of using the same. A bioreactor device of the invention can be used to grow cells and tissue in a controlled in vitro environment. A perfusion bioreactor device of the invention can have multiple perfusion chambers that can be controlled individually. Transverse or parallel flow of a fluid can be provided to each chamber. Cells can be seeded on a hydrogel and/or 3D scaffold to provide a 3D environment in the bioreactor device where the cells can adhere, proliferate, migrate, secrete growth and/or differentiation factors, and/or undergo differentiation, etc. The subject invention also concerns hydrogels and 3D scaffolds that can be used to grow and/or differentiate cells thereon.09-22-2011
20110229969Cell Line for Propagation of Highly Attenuated AlphaViruses - The present invention provides an avian cell that is derived from an avian host cell and stably carries at least one DNA sequence in the cell nucleus encoding an alphavirus polypeptide, a method for preparing such an avian cell, and its use in preparing an alphavirus replican particle.09-22-2011
20100248371METHODS AND COMPOSITIONS FOR MODULATING RAD51 AND HOMOLOGOUS RECOMBINATION - The present invention concerns methods and compositions involving inhibitors and enhancers of RAD51, a protein involved in homologous recombination. In some embodiments, the present invention concerns methods for stimulating homologous recombination, which has a number of significant research and clinical applications. In certain other embodiments, there are methods for protecting cells using a compound that enhances RAD51 activity. Such enhancers may also be employed to prevent or reduce damage to cells that may be caused by DNA damaging agents. In other embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 enhancer or inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.09-30-2010
20090227030Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor - Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.09-10-2009
20090004742SELECTION OF ANTIGEN-SPECIFIC T CELLS - The requirement of T cell activation for efficient expression of genes after messenger ribonucleic acid (mRNA) transfection is leveraged to identify and enrich antigen-specific T cells responding to antigen-pulsed dendritic cells (DCs). RNA transfection of marker genes is used for the selection and enrichment of antigen-specific T cells for use in adoptive immunotherapy. RNA-modified T cells are also used for the generation of enhanced effector populations for use in adoptive immunotherapy. Genes whose transient expression may significantly enhance the in vivo function of T cells (i.e., migratory receptors, anti-apoptotic genes or cytokines enhancing T cell proliferation/differentiation) are used in this modality.01-01-2009
20090004741BIODEGRADABLE POLYPHOSPHORAMIDATES FOR CONTROLLED RELEASE OF BIOACTIVE SUBSTANCES - The present invention is directed to a series of new polycationic biodegradable polyphosphoramidates. Process for making the polymers, compositions containing these polymers and bioactive ligands to enhance the cellular uptake ad intracellular trafficking, articles and methods for delivery of drugs and genes using these polymers are described. A gene delivery system based on these polymers is prepared by complex coacervation of nucleic acid (DNA or RNA) with polymers. Targeting ligands and molecules that could facilitate gene transfer can be conjugated to polymers to achieve selective and enhanced gene delivery. The current invention also provides a complex composition with buffering capacity.01-01-2009
20120142108Compositions For Treating Bacterial Infections - Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described.06-07-2012
20090209037Viral core protein-cationic lipid-nucleic acid-delivery complexes - A nucleic acid delivery complex is provided which comprises a condensed polypeptide/nucleic acid complex and a cationic lipid wherein the complex comprises (a) a nucleic acid sequence of interest (NOI); and (b) one or more viral nucleic acid packaging polypeptides, or derivatives thereof, said polypeptides or derivatives thereof being (i) capable of binding to the NOI; and (ii) capable of condensing the NOI; and wherein the NOI is heterologous to the polypeptide. Also provided is a method of introducing an NOI into a cell using the delivery vector.08-20-2009
20090209039METHOD AND APPARATUS FOR MICROFLUIDIC INJECTION - A method and apparatus for producing a jet or droplet of liquid. An injector device may include a reservoir in fluid communication with a nozzle, and a pressure gradient may be produced in the reservoir (e.g., by a piezoelectric element in an initial direction that is transverse to the emission direction of the jet or droplet) to produce a jet of liquid from the nozzle. The jet or droplet of liquid may be introduced through a cell membrane and into the cell interior in such a way that damage to the cell membrane that would cause cell death is avoided. An electrode may be formed adjacent a fluid channel by conducting a liquid material, such as solder, from a reservoir and into an electrode portion of an electrode channel to a location adjacent the fluid channel. A passageway between the electrode channel and the fluid channel may prevent flow of the liquid electrode material into the fluid channel during electrode formation.08-20-2009
20090209038Cell-Mediated Directed Evolution - The present invention relates to systems which harness the molecular biology of a living cell to direct evolution of biological entities of interest. According to the invention, a host cell is engineered to facilitate mutation of a nucleic acid target corresponding to that entity and select for desirable mutants. As applied to populations of host cells, the invention provides a means to generate and contemporaneously select mutants of interest, allowing for the production of extremely diverse libraries enriched in the most ‘fit’ mutants.08-20-2009
20080261311In vivo incorporation of unnatural amino acids - The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.10-23-2008
20090253207Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells - A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragments from at least two different viruses, such as two different adenoviruses, including adenovirus of subgroup C or subgroup B (for example, adenovirus 16). The protein fragments can comprise a tissue tropism-determining fragment of a fiber protein derived from a subgroup B adenovirus. Also, cells for producing such gene delivery vehicles and pharmaceutical compositions containing these gene delivery vehicles are provided. Further, a method is disclosed for delivering nucleic acid to cells such as smooth muscle cells and/or endothelial cells which involves administering to the cells an adenovirus capsid having proteins from at least two different adenoviruses and wherein at least a tissue tropism-determining fragment of a fiber protein is derived from a subgroup B adenovirus. Particular constructs are also disclosed.10-08-2009
20090246875Efficient method for nuclear reprogramming - This relates to a method of preparing induced pluripotent stem cells, comprising a nuclear reprogramming step with a nuclear reprogramming factor in the presence of miRNA, wherein said miRNA has a property of providing a higher nuclear reprogramming efficiency in the presence of said miRNA than in the absence thereof.10-01-2009
20110143440Mutations caused by activation-induced cytidine deaminase - Methods for causing mutations in genes expressed in eukaryotic cells are provided. The methods involve expressing an activation-induced cytidine deaminase (AID) in the cells. The mutated genes can be any gene that is operably linked to a promoter, where the gene is within about 2 kilobases of the promoter. Examples include antibody genes. Also provided are cells expressing AID. The cells can be from any eukaryote, and include hybridoma cells and myeloma fusion partners.06-16-2011
20100184226MEDIA CONDITIONING FOR IMPROVING GENE DELIVERY EFFICIENCY TO DIFFERENTIATING EMBRYONIC STEM CELLS - The present invention provides systems and methods for improving the efficiency of a transient gene delivery system to differentiating embryonic stem (ES) cells by serum starving the targeted cells for one to three days prior to transfection. Such a serum starvation surprisingly resulted in increased expression of a constitutively-controlled plasmid from 50.4% to 83.2% of the population and increased expression of a promoter/enhancer controlled plasmid from ˜1.4% to ˜3.7% of the population.07-22-2010
20110059530Novel Ecdysone Receptor-Based Inducible Gene Expression System - This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.03-10-2011
20120142107METHOD AND SYSTEM FOR SOMATIC CELL NUCLEAR TRANSFER - Provided is a method for nuclear transfer. An exogenous donor nucleus is introduced into an enucleated oocyte and one or more enucleated sperm cells or one or more enucleate sperm cell fractions are introduced into the oocyte. The one or more sperm cells or one or more sperm cell fractions may be introduced into the oocyte either before, after, or simultaneously, with the donor nucleus. Also provided are cells and embryos produced by the method.06-07-2012
20120142109METHOD FOR PRODUCING T CELL POPULATION UNDER PRESENCE OF RETINOIC ACID - Disclosed is a method for producing a cell population containing memory-like T cells, said method being characterized by including a step for in vitro culturing of a cell population containing T cells or T cell precursor cells using a retinoic acid and a CD3 ligand. Further disclosed is a method for producing a cell population wherein the proportion of memory-like T cells is increased and wherein a desired gene is introduced with a high efficiency and is highly expressed.06-07-2012
20100081201Olig1 mini-promoters - Isolated polynucleotides comprising an OLIG1 promoter are provided, where an OLIG1 regulatory element is operably joined to an OLIG1 basal promoter utilizing a non-native spacing between the promoter and regulatory elements. The promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.04-01-2010
20100068814MULTI-MICRORNA METHODS AND COMPOSITIONS - Provided are DNAs comprising a polynucleotide that encodes at least a first modified miR-30 precursor and a second modified miR-30 precursor. Also provided are vectors comprising the the DNAs, where the vector can replicate in a host cell. Additionally, specific lentiviral vectors comprising the above-described DNA are provided, as are methods of inhibiting expression of a target gene in a eukaryotic cell.03-18-2010
20090111183Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex - This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.04-30-2009
20130137179METHOD FOR EXPRESSING A MOUSE OLFACTORY RECEPTOR OLFR15 ON A CELL MEMBRANE - Provided is a method for effectively expressing mouse olfactory receptor Olfr15 on the cell membrane. The method includes steps of: 05-30-2013
20100304489METHODS AND COMPOSITIONS FOR HOMOLOGOUS RECOMBINATION IN HUMAN CELLS - The methods and compositions described herein are based, in part, on the discovery of a stem cell state in human cells that resembles the morphology observed in murine-derived stem cells. Induction of such a state in human stem cells permits an increase in the efficiency of homologous recombination. Thus, the methods and compositions described herein relate to cells and methods for increasing the efficiency of homologous recombination in human stem cells.12-02-2010
20110177599DELIVERY OF NUCLEIC ACIDS ACROSS MEMBRANES - The present invention provides for methods and compositions for introducing integral membrane proteins into cell membranes and, optionally, delivery of nucleic acids across membranes via the integral membrane proteins.07-21-2011
20100311170METHOD FOR REPROGRAMMING DIFFERENTIATED CELLS - The present invention discloses a method for reprogramming a differentiated cell to an undifferentiated stem cell comprising fusing a pluripotent cell with a differentiated cell to form a fused cell, wherein the pluripotent cell is pre-treated or the fused cell is treated with a suitable amount of a Wnt/β-catenin pathway activator.12-09-2010
20110020935METHOD OF GENE TRANSFER INTO CELLS USING ELECTROSPRAY AND APPARATUS THEREFOR - The present invention provides a method whereby, in transferring a gene into a cell by contacting the cell with a gene to be transferred into the cell in a container and then electrospraying a spray liquid free from the gene on the cell and gene in the container, the gene can be rapidly and conveniently transferred into the cell with high transfer efficiency while minimizing the degradation of the gene, and an apparatus therefor. A nozzle for electrospraying comprising a tube portion for applying a high voltage, which is made of an electrically conductive substance and located on the side of the spray liquid suction port, and another tube portion for spraying, which is made of an insulating substance and located on the side of the spray liquid ejection port. By using this nozzle, electrospraying can be performed while preventing a discharge phenomenon that causes degradation of the gene. Thus, transfer efficiency of the gene into the cell can be remarkably improved, and the gene can be rapidly and conveniently transferred into the cell.01-27-2011
20110111505GENETICALLY ENGINEERED CELLS WHICH EXPRESS BONE MORPHOGENIC PROTEINS - The present invention describes methods of producing cell lines which express recombinant DNA encoding bone morphogenetic proteins (BMP). The cell lines are capable of being implanted in order to enhance the regeneration of tissues through both autocrine and paracrine effects. The cells may further contain DNA encoding receptor proteins which are able to bind to BMPs or enhance or regulate BMP activity.05-12-2011
20090068742Nuclear Reprogramming Factor - There is provided a nuclear reprogramming factor for a somatic cell, which comprises a gene product of each of the following three kinds of genes: an Oct family gene, a Klf family gene, and a Myc family gene, as a means for inducing reprogramming of a differentiated cell to conveniently and highly reproducibly establish an induced pluripotent stem cell having pluripotency and growth ability similar to those of ES cells without using embryo or ES cell.03-12-2009
20090035861RNAi Medicine Having No Adverse Effects - An RNAi reagent and a medicine that have no adverse effects such as interferon and/or cytotoxicity induction are provided.02-05-2009
20110033934Transcriptome Transfer Produces Cellular Phenotype Conversion - The present invention includes methods for effecting phenotype conversion in a cell by transfecting the cell with phenotype-converting nucleic acid. Expression of the nucleic acids results in a phenotype conversion in the transfected cell. Preferably the phenotype-converting nucleic acid is a transcriptome, and more preferably an mRNA transcriptome.02-10-2011
20110033936CANINE iPS CELLS AND METHOD OF PRODUCING SAME - Provided are a method of producing canine iPS cells, comprising (a) the step of bringing into contact with each other a canine somatic cell and a nuclear reprogramming factor, and (b) the step of culturing the cell in a medium containing at least one substance selected from the group consisting of a mitogen-activated protein kinase kinase inhibitor, an activin receptor-like kinase inhibitor, a glycogen synthase kinase inhibitor, a L-type calcium channel agonist and a DNA methylation inhibitor, and a leukemia inhibitory factor, and canine iPS cells that can be obtained by the method.02-10-2011
20110033935RATIONALLY-DESIGNED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN DNASE HYPERSENSITIVE REGIONS OF THE HUMAN GENOME - Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.02-10-2011
20090142839Inducing Premature Senescence to Stabilize Stem Cell Feeder Layer Cells - The present invention provides stem cell feeder layer cell lines that contain are readily triggered to differentiation. The expression vector encodes the senescence-triggering factors (STFs) consisting of Cip/Kip, INK4A, Cy protein or ankyrin-binding protein motifs. Each expression vector also contains an inducible transcription regulation element for conditional expression of the STFs.06-04-2009
20110053273METHODS FOR CLONING AND MANIPULATING GENOMES - Compositions and methods are disclosed herein for cloning a synthetic or a semi-synthetic donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.03-03-2011
20110129927CHINESE HAMSTER APOPTOSIS-RELATED GENES - Provided is an isolated polypeptide comprising a 06-02-2011
20110244574INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) - The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.10-06-2011
20110212530METHOD OF TARGETED GENE DELIVERY USING VIRAL VECTORS - Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.09-01-2011
20090311789METHOD FOR PREPARING DIFFERENTIATED AVIAN CELLS AND GENES INVOLVED IN MAINTAINING PLURIPOTENCY - The present invention relates to a method for preparing differentiated avian cells from stem cells in culture. Genes involved in maintaining the pluripotency of avian stem cells were identified and cloned. By inhibiting the expression of these genes in stem cells, the latter lose their pluripotency characteristics and enter into differentiation. These differentiated cells obtained in vitro can serve as host cells for pathogens, in particular viruses, and can thus be used for the production of antiviral vaccines.12-17-2009
20110250692METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS - The present invention relates to a method for producing mammalian induced pluripotent stem cells, comprising introducing mammal-derived reprogramming factors comprising Oct3/4 and Nanog, or nucleic acids encoding Oct3/4 and Nanog, into mammal-derived somatic cells and thereby inducing induced pluripotent stem cells from the somatic cells, wherein the reprogramming factors comprise neither Sox2 nor nucleic acid encoding Sox2.10-13-2011
20090311788MULTIPLE-COMPARTMENT EUKARYOTIC EXPRESSION SYSTEMS - Method and constructs for expressing heterologous sequences of interest in eukaryotic cells using multiple-compartment expression systems. These systems, which may be comprised of a single construct or multiple constructs, utilize at least two different promoters which are each active within a different subcellular compartment of the same eukaryotic cell. The system and constructs of the invention are particularly useful for achieving enhanced in vivo expression of RNA molecules capable of modulating the expression of target genes.12-17-2009
20090311786Levels and/or Sustainability of DNA-based Gene Expression - The invention encompasses methods for improving the level and/or sustainability of expression for a target nucleic acid in a eukaryotic cell comprising: (a) modifying the target nucleic acid to introduce or to comprise signals that limit or constrain the positions of nucleosome cores, and (b) introducing the modified target nucleic acid into the eukaryotic cell, wherein the modified target nucleic acid has improved levels and/or sustainability of expression compared to original unmodified nucleic acid.12-17-2009
20090311790METHOD OF DIRECTING THE EVOLUTION OF AN ORGANISM - The present disclosure relates to a method of directing the evolution of an organism by modifying the mutation rate of an organism. The increase in genetic diversity may be used to facilitate the selection of a desired hereditary trait in an organism.12-17-2009
20090311787Engineered cleavage half-domains - Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.12-17-2009
20110097803CLDN5 Mini-Promoters - Isolated polynucleotides comprising a CLDN5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.04-28-2011
20090023216Double-Stranded Oligonucleotides - Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.01-22-2009
20080293141Cell for Producing Retrovirus Vector - The N-acetylglucosaminyltransferase III activity is enhanced in a cell carrying retrovirus-origin gag-pol gene and env gene. By constructing a retrovirus vector with the use of the above cell, a retrovirus vector having a modified sugar chain structure can be obtained. The retrovirus vector constructed by this method shows a high infection efficiency particularly in the presence of a functional substance.11-27-2008
20110151566BIODEGRADABLE POLYMERS, COMPLEXES THEREOF FOR GENE THERAPEUTICS AND DRUG DELIVERY, AND METHODS RELATED THERETO - A biodegradable cationic polymer is disclosed, comprising first repeat units derived from a first cyclic carbonyl monomer by ring-opening polymerization, wherein more than 0% of the first repeat units comprise a side chain moiety comprising a quaternary amine group; a subunit derived from a monomeric diol initiator for the ring-opening polymerization; and an optional endcap group. The biodegradable cationic polymers have low cytotoxicity and form complexes with biologically active materials useful in gene therapeutics and drug delivery.06-23-2011
20090142838Methods for expressing rnp particles in eukaryotic cells - Provided herein are nucleic acid constructs and methods for producing or enhancing the production of group II intron RNP particles in eukaryotic cells. The present methods comprise introducing at least one nucleic acid construct comprising a nucleic acid encoding a modified or wild type group II intron RNA and a wild-type or modified group II intron-encoded protein into the eukaryotic cell, and maintaining the cell under conditions that allow for expression of the group II intron RNA and the group II intron-encoded protein in the cell. The nucleic acid encoding the group II intron RNA is operably linked to an RNA polymerase I, an RNA polymerase II, or an RNA polymerase III promoter, and the nucleic acid encoding the group II intron-encoded protein is operably linked to an RNA polymerase II promoter. In certain embodiments, a subcellular localization signal is attached to the group II intron-encoded protein.06-04-2009
20090075383COMPOSITION AND METHOD FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS TO CELLS USING CHITOSAN - There is disclosed a composition and a method for the efficient non-viral delivery of nucleic acids to cells using chitosan. In order to achieve high efficiency of transfection, the composition contains a nucleic acid and a chitosan that has the following physico-chemical properties: a combination of a number-average molecular weight between 8 kDa and 185 kDa and a degree of deacetylation between 72% and 92%. The chitosan molecule can also present additional physiochemical properties such as a block distribution of acetyl groups obtained by a heterogeneous treatment of chitin, and/or a polydispersity index between 1.4 and 7.0. By correctly controlling these parameters, efficient delivery systems may be produced that are effective when optimized for different conditions such as the pH of transfection media and amine-to-phosphate ratio.03-19-2009
20100144040CELLS AND METHODOLOGY TO GENERATE NON-SEGMENTED NEGATIVE-STRAND RNA VIRUSES - The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.06-10-2010
20080268541Attenuated Mycobacteria as Vectors for Gene Delivery to Mammalian Cells - Provided are mycobacteria comprising a recombinant gene operably liked to a mammalian promoter that directs expression of the recombinant gene from a mammalian cell. Also provided are mammalian cells comprising the above mycobacteria. Additionally provided are mycobacterial plasmids capable of replication in a mycobacterium. Further provided are methods of expressing a recombinant gene in a mammalian cell.10-30-2008
20120276636METHOD FOR IMPROVING INDUCED PLURIPOTENT STEM CELL GENERATION EFFICIENCY - The present invention provides a method for improving iPS cell generation efficiency, which comprises a step of introducing a Myc variant having the following features: (1) having an activity to improve iPS cell generation efficiency which is comparative to, or greater than that of c-Myc; and (2) having a transformation activity which is lower than that of c-Myc; or a nucleic acid encoding the variant, in a nuclear reprogramming step. Also, the present invention provides a method for preparing iPS cells, which comprises a step of introducing the above Myc variant or a nucleic acid encoding the variant and a combination of nuclear reprogramming factors into somatic cells. Moreover, the present invention provides iPS cells comprising the nucleic acid encoding the Myc variant which can be obtained by the above method, and a method for preparing somatic cells which comprises inducing differentiation of the iPS cells.11-01-2012
20080213900Engineered Protein Kinases Which Can Utilize Modified Nucleotide Triphosphate Substrates - Engineered protein kinases which can utilize modified nucleotide triphosphate substrates that are not as readily utilized by the wild-type forms of those enzymes, and methods of making and using them. Modified nucleotide triphosphate substrates and methods of making and using them. Methods for using such engineered kinases and such modified substrates to identify which protein substrates the kinases act upon, to measure the extent of such action, and to determine if test compounds can modulate such action. Also Engineered forms of multi-substrate enzymes which covalently attach part or all of at least one (donor) substrate to at least one other (recipient) substrate, which engineered forms will accept modified substrates that are not as readily utilized by the wild-type forms of those enzymes. Methods for making and using such engineered enzymes. Modified substrates and methods of making and using them. Methods for using such engineered enzymes and such modified substrates to identify the recipient substrates the enzymes act upon, to measure the extent of such action, and to measure whether test compounds modulate such action.09-04-2008
20110263026Construction of Protein-Responsive shRNA/RNAi Control System Using RNP Motif - An object of the present invention is to provide an RNAi control system using an RNA-protein interaction motif. The present invention provides an shRNA comprising: a guide strand having a sequence complementary to a target sequence; a passenger strand which forms a duplex with the guide strand; and a linker strand which links the guide strand and the passenger strand, wherein the linker strand comprises an RNP-derived protein-binding motif sequence. The present invention also provides an RNAi control system comprising: the shRNA; and an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA.10-27-2011
20110053272METHODS FOR CLONING AND MANIPULATING GENOMES - Compositions and methods are disclosed herein for cloning a donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.03-03-2011
20100285589GENERATION OF PLURIPOTENT CELLS FROM FIBROBLASTS - Provided are methods and compositions useful for producing and propagating stem cells from fibroblasts.11-11-2010
20110076773Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA - A method of delivering an oligonucleotide or a plasmid expressing an oligonucleotide into a target cell comprises introducing an oligonucleotide into a donor cell, particularly a stem cell, and contacting the target cell with the donor cell under conditions permitting the donor cell to form a gap junction with the target cell, whereby the oligonucleotide or a product of the oligonucleotide is delivered into the target cell from the donor cell.03-31-2011
20100240132HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS - The present invention relates generally to the field of somatic cell nuclear transfer (SCNT) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo.09-23-2010
20090068744VITREOUS CELL LINE - The present invention provides a vitreous cell line capable of expressing an exogenous immortalizing gene, and a production method thereof. Since the vitreous cell line of the present invention can produce a sufficient number of cells and has constant and continuous proliferative capacity, it can be advantageously utilized for the elucidation of the pathogenesis of retinal vitreous diseases, and the development of a drug for the prophylaxis and/or treatment of retinal vitreous diseases. Moreover, the cell line is not only highly useful for the biochemical-physiological studies of the vitreous body, and further for the study of cell differentiation mechanisms, but also possibly usable as a biological material of an artificial vitreous body.03-12-2009
20090203140Genomic editing in zebrafish using zinc finger nucleases - Disclosed herein are methods and compositions for genomic editing of one or more genes in zebrafish, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.08-13-2009
20100190256METHOD FOR CULTURING MAMMALIAN TASTE CELLS - The invention provides methods of culturing mammalian taste cells, including taste receptor cells. Cells are maintained for a duration of up to three months and longer while maintaining molecular and functional characteristics of mature taste cells. The cells are cultured on coated cell culture vessels and, from first replacement of medium onwards, the medium is replaced in intervals of at least 5 days. The invention further provides isolation and culturing methods of taste cells wherein the time that the cells are exposed to isolation solution and proteolytic enzymes is minimized and the cells are cultured in coated culture vessels with the medium replaced in intervals of at least 5 days from first replacement onwards. The invention further provides cultured taste cells, transfection and assay methods, and taste cell assay buffers with an osmolarity of about 300-320 and pH of about 7.0-7.3.07-29-2010
20110189775Targeted genomic alteration - Disclosed herein are methods and compositions for targeted integration and/or targeted excision of one or more sequences into a cell, for example, for expression of one or more polypeptides of interest.08-04-2011
20110136235MK167 Mini-Promoters - Isolated polynucleotides comprising an MKI67 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.06-09-2011
20110263025BIODEGRADABLE POLYDISULFIDE AMINES FOR GENE DELIVERY - Poly(disulfide amine)s, methods of making, and methods of use are described. Illustrative embodiments of the poly(disulfide amine)s include poly(N,N′-cystaminebisacrylamide-spermine), poly(N,N′-cystaminebisaciylamide-N,N′-bis(3-aminopropyl)1,3-propanediamine), poly(N,N′-cystaminebisacrylamide-N,N′-bis(3-amino-propyl)ethylenediamine), poly(N,N′-cystaminebisacrylamide-N,N′-bis(2-aminoethyl)-1,3-propanediamine), and poly(N,N′-cystaminebisacrylamide-triethylenetetramine). These compositions are made by Michael addition between N,N′-cystaminebisacrylamide and protected oligoamine monomers, followed by deprotection. Complexes are formed by mixing the poly(disulfide amine)s with a nucleic acid. Delivery of the nucleic acid into cells is carried out by contacting the cells with the nucleic acid/poly(disulfide amine) complexes.10-27-2011
20100029003System and methods for identifying miRNA targets and for altering miRNA and target expression - The present invention generally relates to microRNAs such as vertebrate microRNA (miRNA), for example, mammalian miRNA. Various aspects of the invention are directed to the detection, production, or expression of miRNA. In one aspect, the invention provides systems and methods for identifying targets of miRNA sequences. For instance, in one embodiment, gene sequences comprising UTRs are compared with miRNA sequences to determine the degree of interaction, for example, by determining a free energy measurement between the miRNA sequence and the UTR, and/or by determining complementarity between at least a portion of the miRNA sequence and the UTR. In another aspect, the invention is directed to the regulation of gene expression using miRNA. For example, gene expression within a cell may be altered by exposing the cell to an oligonucleotide comprising a sequence that is substantially antisense to at least a portion of an miRNA region of the gene, for example, antisense to a 6-mer or 7-mer portion of the miRNA. In still another aspect, the invention is directed to the treatment of cancer. For instance, in one set of embodiments, an isolated oligonucleotide comprising a sequence that is substantially antisense to an miRNA, or a portion of an miRNA, is administered to a subject having or being at risk of cancer. Yet other aspects of the invention are directed to compositions or kits including oligonucleotides comprising a sequence that is substantially antisense to an miRNA (or a portion of an miRNA), methods of promoting any of the above aspects, or the like.02-04-2010
20100022005ADIPOSE STROMAL STEM CELLS FOR TISSUE AND VASCULAR MODIFICATION - Methods are provided for isolating adipose derived stromal cells from an animal by extracting adipose tissue from the patient, dissecting the tissue, dissociating the tissue into a cell suspension, removing the adipocytes, exposing the cell suspension to red cell lysis buffer, and isolating adipose derived stromal cells.01-28-2010
20100129914Tol1 FACTOR TRANSPOSASE AND DNA INTRODUCTION SYSTEM USING THE SAME - An object is to provide a Tol1 element transposase and a use thereof. Provided is a Tol1 element transposase containing (a) a protein having the amino acid sequence of SEQ ID No: 1 or (b) a protein having an amino acid sequence homologous to the amino acid sequence of SEQ ID NO: 1 and having an enzymatic activity for transferring Tol1 element. Further, provided are a polynucleotide encoding the transposase and an expression construct containing the polynucleotide therein. The present invention also provides a DNA introduction system including (a) a donor factor having such a structure that a desired DNA is inserted in a transposase gene-defected Tol1 element and (b) a helper factor containing the transposase or the polynucleotide.05-27-2010
20110070650Method of Enhancing Homologous Recombination of Somatic Cells and Method of Acquiring Specific Antibody - The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes.03-24-2011
20100190257Self-Assembly of a Cell-Microparticle Hybrid - The present invention provides a fabrication method for the formation of a cell-microparticle hybrid. A biotin-avidin binding system also employs the use of a biodegradable polymer and any cell type that self-assemble to form a hybrid system.07-29-2010
20090047742Inhibition of mRNA Interferase-Induced Apoptosis in BAK-Deficient and BAK- and Bax-Deficient Mammalian Cells - Ribonucleases, antibiotics, bacterial toxins and viruses inhibit protein synthesis, which results in apoptosis in mammalian cells. How the BCL-2 family of proteins regulates apoptosis in response to shutoff of protein synthesis is not known. According to the present invention, an 02-19-2009
20110117653METHOD FOR PRODUCTION OF PLURIPOTENT STEM CELL - The present invention relates to a method for production of a cell population containing a pluripotent stem cell, said method comprising a step of treating a somatic cell which has been contacted with nuclear reprogramming factors under nutrient-starved condition, and/or a step of treating the somatic cell with an agent capable of arresting cell cycle. The present invention allows induction and growth of pluripotent stem cells at high frequency, and it also allows production of pluripotent stem cells with high efficiency. The nuclear reprogramming factors to be used may be any selected from the group consisting of OCT4, SOX2, c-MYC, KLF4, NANOG and LIN28.05-19-2011
20090061521Recombinant negative strand RNA virus expression systems and vaccines - The present invention relates methods of generating infectious negative-strand virus in host cells by an entirely vector-based system without the aid of a helper virus. In particular, the present invention relates methods of generating infectious recombinant negative-strand RNA viruses intracellularly in the absence of helper virus from expression vectors comprising cDNAs encoding the viral proteins necessary to form ribonucleoprotein complexes (RNPs) and expression vectors comprising cDNA for genomic viral RNA(s) (vRNAs) or the corresponding cRNA(s). The present invention also relates to methods of generating infectious recombinant negative-strand RNA viruses which have mutations in viral genes and/or which express, package and/or present peptides or polypeptides encoded by heterologous nucleic acid sequences. The present invention further relates the use of the recombinant negative-strand RNA viruses or chimeric negative-strand RNA viruses of the invention in vaccine formulations and pharmaceutical compositions.03-05-2009
20100003757METHODS FOR THE PRODUCTION OF IPS CELLS USING NON-VIRAL APPROACH - Methods and composition of induction of pluripotent stem cells and other desired cell types are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells are described. Furthermore, the invention provides induced pluripotent stem cells and desired cell types essentially free of exogenous vector elements with the episomal expression vectors to express differentiation programming factors.01-07-2010
20100330677Improved Reprogramming of Mammalian Cells, and Cells Obtained - Expression of reprogramming factors such as Sox2, klf4, c-myc, Nanog, LIN28 and Oct4 followed by culture in a MEK inhibitor and a GSK3 inhibitor reprograms tissue cells. The invention provides new uses of these inhibitors, for example in inducing completion of the transcriptional resetting of so-called pre-pluripotent (pre-iPS) stem cells, for example as obtained from mammalian neural stem cells or epiblast stem cells treated with single or combinations of the reprogramming factors, expressed transiently or by integrative vectors. Also provided are systems for reprogramming an epiplast stem cells independently of the use of there inhibitors.12-30-2010
20100136694Cone-Shaped Adapter for a Gene Gun - A cone-shaped adapter for attachment to a muzzle of a gene gun is generally provided. The cone-shaped adapter comprises sidewalls that taper from a base plane at one end and to an apex aperture at an opposite end and a fitting. The sidewalls form a base angle of from about 85° to about 45° with the base plane. The fitting is attached to the sidewalls at the base plane and is configured to connect the cone-shaped adapter to the muzzle of the gene gun. Methods of using the cone-shaped adapter with a gene gun are also provided.06-03-2010
20110306138COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY - The use of at least one nucleic acid based nuclear localization signal including a natural or synthetic m12-15-2011
20090117657Preparation For Transferring Nucleic Acid Into Cell - The present invention provides a composition comprising a polysaccharide to enhance transfection of a cell with a nucleic acid. The present invention also provides a method for transfecting a cell with a nucleic acid comprising the steps of forming a polyionic complex of the nucleic acid and a polysaccharide; and bringing about uptake of the polyionic complex by the cell. Preferably, the cell is selected from bone marrow mesenchymal stem cells, nervous system cell lines, adipose tissue stem cells, immunocytes, neurons, and chondrocytes. Moreover, preferably the polysaccharide is a cationized pullulan derivative, a cationized dextran derivative, or a cationized mannan derivative.05-07-2009
20110306137METHODS AND COMPOSITIONS FOR MODULATING DIFFERENTIATION OF PLURIPOTENTIAL CELLS - Methods and compositions useful for altering the differentiation potential of marrow adherent stromal cells, also known as mesenchymal stem cells are disclosed. The normal tendency for these cells to differentiate into osteogenic and adipogenic lineages is restricted.12-15-2011
20090111184Chromosome selection - Systems, methods, compositions and apparatus relating to genome, chromosome, and mitochondria selection are disclosed.04-30-2009
20090004740PRIMATE TOTIPOTENT AND PLURIPOTENT STEM CELLS PRODUCED BY SOMATIC CELL NUCLEAR TRANSFER - Purified totipotent stem cells and pluripotent stems cells derived by somatic cell nuclear transfer are disclosed herein, as well as cell lines, multipotent cells and differentiated cells produced from these stem cells. The stem cells are produced from an enucleated host cell from a first donor and nuclear genetic material from a somatic cell of a second donor. Methods for making and using such compositions of such stem cells are also provided.01-01-2009
20080293142Multiple shRNA Expression Vectors and Methods of Construction - A research or therapeutic tool for RNA interference (RNAi) is a single vector that expresses multiple short hairpin RNA (shRNA) sequences.11-27-2008
20100062533Nuclear reprogramming factor and induced pluripotent stem cells - The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.03-11-2010
20120003741HEPATITIS C VIRUS EXPRESSING REPORTER TAGGED NS5A PROTEIN - The present inventors developed hepatitis C reporter viruses containing Core through NS2 of prototype isolates of all major HCV genotypes and the remaining genes of isolate JFH1, by insertion of reporter genes in domain III of HCV NS5A. The inventors have identified a deletion upstream of the inserted reporter gene sequence, which conferred favourable growth kinetics in Huh7.5 cells to these viruses. These reporter viruses can be used for high throughput analysis of drug and vaccine candidates as well as patient samples. Drugs could be evaluated for their potential to prevent infection or cure infected cells. The neutralizing capacity of antibodies induced by vaccine candidates could be evaluated in order to define successful vaccination strategies. Broadly neutralizing antibodies could be identified testing engineered antibodies and antibodies derived from serum of HCV infected individuals; thus this technique could contribute to the development of immunotherapy. The developed systems could aid individualized treatment of HCV infected: Patient isolates could be tested for resistance to drugs by introduction of genome regions involved in drug resistance in the developed constructs and subsequent treatment with the drug of interest. The present inventors also developed JFH1-based intergenotypic recombinants with genotype specific homotypic 5UTR, or heterotypic 5′UTR (either of genotype 1a (strain H77) or of genotype 3a (strain S52)). The present inventors additionally developed J6/JFH1 recombinants with the 5′UTR of genotypes 1-6. These recombinants with different 5UTRs are a useful to study the function of the 5′UTR in a genotype specific manner.01-05-2012
20090253206NUCLEAR TRANSPORT AGENT AND METHOD FOR PRODUCING SAID AGENT - The present invention relates to a transport agent for transporting nucleic acids into eukaryotic cells and a method for producing said agent. The invention further concerns methods for transporting nucleic acids into eukaryotic cells using the transport agent according to the invention. The present invention provides an alternative transport agent and a method which are effective to allow an efficient transport of nucleic acids into eukaryotic cells. The transport agent comprises a complex forming moiety that is capable of forming complexes with at least one nucleic acid molecule and condensing said nucleic acid molecule, and at least one nuclear localization moiety comprising at least one nuclear localization signal and having an approximately neutral net charge.10-08-2009
20100184227PLURIPOTENT STEM CELLS OBTAINED BY NON-VIRAL REPROGRAMMING - Methods for reprogramming primate somatic cells to pluripotency using an episomal vector that does not encode an infectious virus are disclosed. Pluripotent cells produced in the methods are also disclosed.07-22-2010
20120208278INNATE IMMUNE SUPPRESSION ENABLES REPEATED DELIVERY OF LONG RNA MOLECULES - The present invention relates in part to methods for suppressing the innate immune response of a cell to transfection with an exogenous nucleic acid, to methods for increasing expression of a protein encoded by an exogenous nucleic acid by repeated delivery of the exogenous nucleic acid to a cell, and to methods of changing the phenotype of a cell by differentiating, transdifferentiating or dedifferentiating cells by repeatedly delivering one or more nucleic acids that encode defined proteins. A method is provided for extended transient transfection by repeated delivery of an in vitro-transcribed RNA (“ivT-RNA”) to a cell to achieve a high and sustained level of expression of a protein encoded by an ivT-RNA transcripts.08-16-2012
20120009682METHOD FOR SELECTING A HIGH EXPRESSION RECOMBINANT CELL LINE - The present invention relates to a method of selecting high producer clones by using an expression vector, the expression vector comprising: (i) a gene expression cassette comprising a selectable marker gene to which polyA has been inoperably linked; and (ii) a gene expression cassette which encodes a recombinant protein of interest and to which polyA has been operably linked. According to the invention, high producer clones can be selected from cell populations at least 10 times fewer than in the existing methods of selecting cell lines. Particularly, high producer clones can be selected using a low concentration of MTX compared to a conventional stepwise gene amplification strategy which comprises carrying out multiple amplification steps while increasing the concentration of MTX. Accordingly, the development period of cell lines can be shortened and the labor and cost required for selection of high-productivity cell clones can be reduced, whereby more efficient production of proteins is possible even when general selectable marker genes other than MTX are used.01-12-2012
20120129261Transcriptome Transfer Produces Cellular Phenotype Conversion - The present invention includes methods for effecting phenotype conversion in a cell by transfecting the cell with phenotype-converting nucleic acid. Expression of the nucleic acids results in a phenotype conversion in the transfected cell. Preferably the phenotype-converting nucleic acid is a transcriptome, and more preferably an mRNA transcriptome.05-24-2012
20120129262Methods of Modifying Transcriptional Regulatory Networks in Stem Cells - The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and identified formulations for research and therapeutic purposes. Nevertheless, other cell types have yet to be isolated and propagated from normal cells and methods of isolating said novel cell types as well as methods for introducing perturbations into the transcriptional regulatory network in order to construct a computer model of the entire human transcriptional regulatory network would greatly benefit basic research as well as manufacturing technology for cell-based therapies.05-24-2012
20110165682Human Trophoblast Stem Cells and Use Thereof - Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies.07-07-2011
20110165681Light-Activated Proton Pumps and Applications Thereof - In a method for adjusting the voltage potential or pH of, or cause proton release from, cells, subcellular regions, or extracellular regions, a gene encoding for a light-driven proton pump is incorporated into at least one target cell or region, the proton pump operating in response to a specific wavelength of light. Expression of the gene is caused by exposing the target cell or region to the specific wavelength of light in a manner designed to cause the voltage potential adjustment, pH adjustment, or proton release. The proton pump may be a microbial rhodopsin, in particular derived from the 07-07-2011
20120115232METHOD FOR INDUCING DEGRADATION OF PROTEIN IN MAMMALIAN CELL - Provided is a system which can induce the degradation of a protein of interest in a mammalian cell system reliably and stably within a short time. A mammalian cell inducible for protein degradation, the degradation of a protein of interest being induced by an auxin, in which the mammalian cell has both a TIR1 family protein gene from rice and a chimeric gene expressing a protein of interest labeled with a plant Aux/IAA family protein.05-10-2012
20120058562REPROGRAMMING IMMORTALIZED B CELLS - Methods and composition for providing induced pluripotent stem (iPS) cells are provided. For example, in certain aspects methods including reprogramming B lymphocytes transformed by episomal vectors such as Epstein-Barr virus-based vectors are described. Furthermore, the invention provides induced pluripotent stem cells essentially free of exogenous elements and having B cell immunoglobin variable region rearrangement.03-08-2012
20120064630EUKARYOTIC HOST CELL COMPRISING AN EXPRESSION ENHANCER - Invention relates to a eukaryotic host cell comprising a recombinant nucleotide sequence encoding an expression enhancer, which is selected from the group consisting of cLC52, RPL33 and cLC61, and its use in a method of producing a protein of interest (POI).03-15-2012
20120156785METHODS AND PRODUCTS FOR BIASING CELLULAR DEVELOPMENT - Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.06-21-2012
20110091973Modified and fusion enhanced erythrocytes, cells and uses thereof - Modified fusion enhanced erythrocytes (or other cell types and synthetic cells) including human viral receptor proteins, human viral coreceptor proteins and viral derived proteins capable of mediating entry of respective viruses into the modified erythrocytes, cells or pseudo-cells and the method of using the fusion enhanced modified erythrocytes, cells or pseudo-cells for the treatment or prevention of viral infections. The fusion enhanced modified erythrocytes comprises CD4 and at least one HIV coreceptor, such as CXCR4 or CCR5 and as well, at least one of cholesterol rafts, fusin, actin, a viral derived protein such as fusion peptide derived from HIV GP120 or HIV GP41 or a shorter protein derived from a long viral protein, such as a portion of HIV derived GP120, or HIV GP41 such as the 23 N-terminal peptide of the HIV-1 gp 41 protein (AVGIGALFLGFLGAAGSTMGARS) called FP23 (Fusion Peptide). These viral-fusion enhanced cells may also be electrostatic charge enhanced through further additions named in this invention. The modified erythrocytes, when administered to an HIV patient, bind to the plasma virus and induce the injection of the HIV ribonucleoprotein complex into the cells. The entrapped viral content is sequestered within said cell for at least the period of time that the cell maintains its outer membrane integrity. The virus is thereafter either degraded or deactivated within the erythrocytes, cells or pseudo-cells, or destroyed by erythrophagocytosis.04-21-2011
20110039338METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS - Provided is a method of improving the efficiency of establishment of induced pluripotent stem cells, comprising culturing somatic cells under hypoxic conditions in the step of nuclear reprogramming thereof.02-17-2011
20110065192Embryonic stem cell line and method for preparing the same - An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.03-17-2011
20100093094TRIAZINE DENDRIMERS AND METHODS OF MAKING AND USING THE SAME FOR NUCLEIC ACID TRANSPORT - According to one embodiment, the disclosure relates to a dendrimer complex usable for transfection of a cell and including a nucleic acid to be transfected non-covalently bound to a triazine dendrimer vector. According to another embodiment, the disclosure provides a method of transfecting a cell by contacting the cell with a dendrimer complex as described above. After the contact, the dendrimer complex enters the cell. According to a third embodiment, the disclosure relates to a method of making a triazine dendrimer complex for cell transfection by covalently bonding a series of triazine monomers to a central monomer through a series of reactions to form a triazine dendrimer, then non-covalently bonding a nucleic acid to the dendrimer to form a triazine dendrimer complex operable to transfect a cell.04-15-2010
20120122225CARRIER PEPTIDE FRAGMENT AND USE THEREOF - The method for transferring a foreign substance provided by the present invention includes the steps of: preparing a construct for transferring a foreign substance that contains a carrier peptide fragment including either the amino acid sequence WRRQARFK (SEQ ID NO. 1) or any amino acid sequence formed by the substitution, deletion, and/or addition (insertion) of 1, 2, or 3 amino acid residues in the amino acid sequence, and a foreign substance of interest that is bonded to the N-terminus and/or C-terminus of the carrier peptide fragment; supplying the construct for transferring a foreign substance to a test sample that contains a target eukaryotic cell; and incubating the test sample that has been supplied with the construct for transferring a foreign substance to thereby transfer the construct into the eukaryotic cell in the test sample.05-17-2012
20090130761Freeze-Dried Product for Introducing Nucleic Acid, Oligonucleic Acid or Derivative Thereof - A freeze-dried product is provided which, together with demonstrating satisfactory ability to express function when used to introduce a gene or antisense nucleic acid and the like, enables concentration to be adjusted easily, offers easy handling and has superior storage performance.05-21-2009
20090130759Culture Medium Containing Kinase Inhibitor, and Use Thereof - Pluripotent cells are maintained in a self-renewing state in serum-free culture medium comprising a gp130 agonist (LIF) and a GSK3 inhibitor.05-21-2009
20120315703CELLS AND METHODS FOR OBTAINING THEM - Reprogrammed somatic cells, methods for reprogramming, reprogramming factors for somatic cells and uses of such factors and cells are described. Nuclear reprogramming factors [NRF] described comprise one or more of a gene product or a polynucleic acid encoding a gene product from a retinoic acid receptor (RAR/RXR) family member, or an agonist or antagonist thereof; a gene product from an Lrh1 family member; or an agonist thereof; retinoic acid or a gene product involved in synthesizing or metabolizing retinoic acid; or an agonist or antagonist thereof; or a gene product that is involved in transporting a retinoic acid family member.12-13-2012
20120164734NUCLEOTIDES ENCODING STOP CODONS IN MULTIPLE READING FRAMES AND METHODS OF USE - Compositions having polynucleotides encoding multiple translational stop signals in more than one reading frame are provided. The compositions include isolated polynucleotides, expression cassettes, and vectors, as well as host cells, prokaryotic organisms, and eukaryotic organisms comprising the polynucleotide(s). Methods include using the polynucleotides to stop translation of an mRNA into a protein, to produce a transformed cell and/or organism comprising the polynucleotide, and to identify transformed cells or organisms of a specific lineage.06-28-2012
20120135525REPROGRAMMING T CELLS AND HEMATOPOIETIC CELLS - Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD3405-31-2012
20120220037METHODS AND MATERIALS FOR PRODUCING TRANSGENIC ARTIODACTYLS - Swine animal models comprising a genomic disruption of an endogenous gene chosen from the group consisting of a Low-Density Lipoprotein Receptor gene LDLR, Duchene's Muscular Dystrophy (DMD) gene, and hairless gene (HR). Methods of preparing transfected cells useful for making a transgenic animal comprising exposing a first group of cells to a transfection agent and reseeding the group with additional cells that have not been exposed to the agent. The transgenic animals are useful for medical and scientific animal models of human diseases and conditions, as well as sources for cells, tissues, and biomaterials.08-30-2012
20120178167Methods for Transfecting Nucleic Acid Into Live Cells - The present invention includes methods for transferring a multigenic phenotype to a cell by transfecting, preferably by phototransfection, and locally transfecting a cell or a cellular process with a laser while the cell is bathed in a fluid medium comprising two or more nucleic acids, thereby introducing the nucleic acid into the interior of the cell. Expression of the nucleic acids results in a multigenic phenotype in the tranfected cell.07-12-2012
20120178166SIMPLIFIED BASIC MEDIA FOR HUMAN PLURIPOTENT CELL CULTURE - Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described.07-12-2012
20120178168METHOD FOR REGULATING PROTEIN FUNCTION IN CELLS USING SYNTHETIC SMALL MOLECULES - Methods and compositions for the rapid and reversible destabilizing of specific proteins using cell-permeable, synthetic molecules are described. Stability-affecting proteins, e.g., derived from FKBP and DHFR proteins are fused to a protein of interest and the presence or absence of the ligand is used to modulate the stability of the fusion protein.07-12-2012
20090068743CATIONIC ALPHA-AMINO ACID-CONTAINING BIODEGRADABLE POLYMER GENE TRANSFER COMPOSITIONS - The invention provides gene transfer compositions using as the gene carrier a biodegradable polymer that contains one or more cationic alpha amino acids, such as arginine or agmatine. The compositions form a tight soluble complex with a poly nucleic acid suitable for transfecting target cells to effect translation of the cargo poly nucleic acid by the target cell. Thus, such compounds are useful both in vitro and in vivo.03-12-2009
20090111185Female genome selection - Systems, methods, compositions and apparatus relating to genome, chromosome, and mitochondria selection are disclosed.04-30-2009
20100291682SYSTEM FOR TRANSPOSING HYPERACTIVE RECOMBINANT DERIVATIVES OF MOS-1 TRANSPOSON - The invention concerns a system for transposing a hyperactive recombinant derivative of Mos-1 transposon, comprising at least the two following partners: a) a Mos-1 pseudo-transposon in which an exogenous nucleotide sequence of interest replaces the nucleotide sequence encoding the original Mos-1 transposase; and b) a Mos-1 tranposase provided in trans in said pseudo-transposon, at least one of said partners being appropriately genetically modified to improve the transposition frequency of said exogenous nucleotide sequence of interest. Additionally to such systems, the invention concerns hyperactive Mos-1 transposons, hyperactive Mos-1 transposases, kits. The invention further concerns the use of one or more of abovementioned means for carrying out sequence transpositions, and more particularly efficient gene transfers.11-18-2010
20120083037Non-Viral Transfection Agent - The invention relates to a non-viral transfection agent comprising polymer/nucleic acid complexes and nanofibers, wherein the polymer/nucleic acid complexes are composed of at least one nucleic acid and at least one cationic polymer. The nanofibers carry the polymer/nucleic acid complexes, wherein the non-viral transfection agent is advantageously produced by means of electrospinning. The cationic polymer is favorably a polyimine or polyethyleneimine and can be modified with one or more hydrophilic polymers coupled thereto. It can also be advantageous to couple the cationic polymer with one or more carbohydrates and/or with a receptor-specific ligand. The nucleic acid is a DNA or an RNA, or a DNA or RNA derivative, advantageously a therapeutically active nucleic acid. The nanofibers are composed of biodegradable, biocompatible polymers. The nanofibers or the entire transfection agent can be provided with a polymer coating. A method for producing a non-viral transfection agent comprises the following steps: providing the polymer/nucleic acid complex, producing a spinning solution containing the polymer/nucleic acid complexes, and electrospinning.04-05-2012
20120258538CULTURE METHOD FOR HEMATOPOIETIC STEM CELLS - By culturing hematopoietic stem cells in the presence of SFRP-F protein, hematopoietic stem cells for hematopoietic stem cell transplantation can be produced.10-11-2012
20090017542High-efficiency wild-type-free AAV helper functions - The present invention provides methods and compositions for producing high titer, wild-type-free preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include novel nucleic acids encoding AAV helper functions and AAV helper function vectors. The present invention also includes host cells transfected by the claimed nucleic acids, methods of using the claimed vectors, and rAAV virions produced by such methods.01-15-2009
20110124108EPIGENETIC ENGINEERING - The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines.05-26-2011
20120231545METHOD FOR MODIFYING BOVINE EMBRYO STEM CELLS AND METHOD FOR PURIFYING PROTEINS PRODUCED BY MODIFIED BOVINE EMBRYO STEM CELLS - The present invention relates to the modification process of bovine embryonic stem cells and purification process of proteins generated by modified stem cells. In particular, the present invention lies in the field of medicine and veterinary.09-13-2012
20100330675INSULATING POLYNUCLEOTIDES DERIVED FROM ELEMENT D4Z4 AND THEIR USES IN TRANSGENESIS - Polynucleotides with insulating properties allowing protection of the expression of a transgene from adjacent cis elements in higher eukaryotic cells. In particular, these polynucleotides can be used for transgenesis, gene therapy and the production of recombinant proteins.12-30-2010
20100120155CONSTRUCTION OF FULLY-DELETED ADENOVIRUS-BASED GENE DELIVERY VECTORS AND USES THEREOF - The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.05-13-2010
20080299659NUCLEIC ACID COMPOUNDS FOR INHIBITING APOB GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ApoB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ApoB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ApoB gene in a cell or in a subject to treat an ApoB-related disease.12-04-2008
20090215178Methods to enhance the stability and homogeneity of transgene expression in clonal cell lines - Strategies for increasing the productivity of recombinant protein expression in isogenic cell-lines. Development of a novel selection system for the improved stability and homogeneity of transgene expression in isogenic cells without the dependence on continuous selective drugs.08-27-2009
20120264218INDUCTION OF PLURIPOTENT CELLS - The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.10-18-2012
20100203641METHODS AND COMPOSITIONS FOR EXPRESSING NEGATIVE-SENSE VIRAL RNA IN CANINE CELLS - The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.08-12-2010
20100203640Antigen Presenting Cells - The present invention relates to a method for inducing specific long-lasting robust immunological tolerance towards at least one polypeptide derived from at least one allergen by transplanting a hematopoietic (stem) cell which is produced to display the said at least one polypeptide derived from at least one allergen.08-12-2010
20120270321REVERSE GENETICS SYSTEMS - The invention provides various reverse genetics systems for producing segmented RNA viruses, wherein the systems do not require bacteria for propagation of all of their expression constructs.10-25-2012
20110212529Muscle-specific expression vectors - The invention is directed to novel combinations of muscle-specific enhancers and promoter elements useful for achieving persistent expression in the muscle or myocyctes. The muscle-specific promoter elements are derived from a muscle creatine kinase promoter, a troponin I promoter, a skeletal alpha-actin promoter, or a desmin promoter. The muscle-specific enhancer elements are derived from either troponin I internal regulatory elements, muscle creatine kinase enhancers, or desmin enhancers.09-01-2011
20100184225USE OF A CELLULAR EXTRACT FOR A MITOTIC REMODELING OF CHROMOSOMES - The present invention relates to the use of a female germinal cell (egg) extract of pluricellular organisms in M-phase of the cell cycle for a mitotic remodeling of chromosomes of donor cells of pluricellular organisms, wherein the mitotic remodeling confers to the nucleus of the donor cells the ability to adapt themselves to the early embryonic development, in particular to the replication phases, in order to carry out the embryonic development or to obtain stem cells.07-22-2010
20110236977DENTAL STEM CELL DIFFERENTIATION - Provided is a method of preparing an embryonic stem cell-like cell, a method of preparing an insulin-secreting cell or pancreatic beta-like cell, a method of preparing a chondrocyte-like cell, a method of preparing a myocyte-like cell, and a method of preparing a hair follicle-like cell. A composition comprising a dental stem cell and an insulin-secreting cell or a pancreatic beta-like cell is also provided. Further, a composition comprising (a) a dental stem cell and (b) a chondrocyte-like cell, a myocyte-like cell, or a hair follicle-like cell is provided. Additionally provided is an insulin-secreting cell or a pancreatic beta-like cell differentiated from a dental stem cell. Further provided is a chondrocyte-like cell, a myocyte-like cell, or a hair follicle-like cell, derived from a dental stem cell.09-29-2011
20110294219USE OF THE FOAMY VIRUS BET PROTEIN FOR INACTIVATING APOBEC - Described is the foamy virus Bet-mediated inactivation of the mutagenic, genome-modifying and vector-inactivating cellular enzyme ABOBEC. Such inactivation is useful for the treatment or prevention of various diseases, e.g., cancer, or for enhancing the production and genetic stability of gene therapy vectors, preferably retroviral vectors.12-01-2011
20120100615CELL FATE CONVERSION OF DIFFERENTIATED SOMATIC CELLS INTO GLIAL CELLS - The present invention relates to the reprogramming of differentiated somatic cells, such as those differentiated cells that arise from embryonic mesoderm, into glial cells. Glial cells produced from this reprogramming are functionally equivalent to glial cells that arise from ectodermal origins.04-26-2012
20120100614Method for production of anti-tumor TRAIL protein - The method for production of anti-tumor TRAIL comprises: inserting a TRAIL molecule, encoded by a viral vector irreversibly derived from a cell line, into a carrier cell, thereby obtaining a stably TRAIL-producing carrier cell, said TRAIL molecule comprising a soluble molecule.04-26-2012
20100190258METHOD OF PRODUCING RECOMBINANT BIOLOGICAL PRODUCTS - A method of producing a recombinant biological product, which method employs a mammalian producer cell culture, comprises the steps of generating a biomass of mammalian producer during an initial phase of cell culture, and causing an increase in a level of one or more of the miRNA molecules of Table 1 within the mammalian producer cells once a desired concentration of mammalian producer cells has been achieved. The method may also comprise the step of increasing a level of an inhibitor of one or more of the miRNA molecules of Table 1 within the mammalian producer cells at the start of or during an initial phase of culture.07-29-2010
20110136236GENETICALLY MODIFIED EUKARYOTIC CELLS - The invention relates to a method of producing genetically modified eukaryotic cells with optimised growth characteristics wherein a recombinant first nucleotide sequence has been integrated into a desired position in the genome. The sequence contains at least one gene encoding a plasma membrane protein with either toxin-receptor or toxic properties and allowing for surface expression based cell sorting to identify a suitable genomic integration locus. The invention also relates to a second exogenous nucleotide sequence containing at least one protein of interest as well as a vector, which aids in the site specific exchange of the first with the second nucleotide sequence. Efficient exchange is achieved by a stringent selection strategy that will kill all cells still expressing the plasma membrane protein.06-09-2011
20110159592COMPOSITION FOR REPROGRAMMING SOMATIC CELLS TO GENERATE INDUCED PLURIPOTENT STEM CELLS, COMPRISING Oct4 IN COMBINATION WITH Bmi1 OR ITS UPSTREAM REGULATOR, AND METHOD FOR GENERATING INDUCED PLURIPOTENT STEM CELLS USING THE SAME - Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for Bmi1; and b) an Oct4 protein or a nucleic acid molecule coding for Oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the genetic factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.06-30-2011
20080254540METHODS OF GENETICALLY ENCODING UNNATURAL AMINO ACIDS IN EUKARYOTIC CELLS USING ORTHOGONAL tRNA/SYNTHETASE PAIRS - This disclosure concerns compositions and methods for genetically encoding and expressing prokaryotic tRNAs in eukaryotic cells. In some embodiments, the disclosure concerns methods and compositions for expressing unnatural amino acids in eukaryotic cells using orthogonal tRNA/synthetase pairs. In certain embodiments, the methods involve expressing prokaryotic tRNA/synthetase pairs in eukaryotic cells, for instance mammalian cells or yeast cells (such as those that are NMD-deficient), under the control of a pol III promoter, for instance a type-3 pol III promoter or an internal leader promoter. Also provided are cell lines that are NMD-deficient and methods of increasing the efficiency of UAA incorporation in a cell that include de-activating the NMD pathway in the cell. Also provided are methods increasing the efficiency of incorporation of an unnatural amino acid in a cell by disrupting a Nonsense-Mediated mRNA Decay—(NMD) pathway in the cell.10-16-2008
20090186413MUSSEL ADHESIVE PROTEIN AS GENE DELIVERY - The present invention is related to a composition and a method for delivering a nucleic acid into a cell. The invention also provides a biocompatible and biodegradable gene delivery composition and methods of use and making thereof.07-23-2009
20080220527MODULAR TRANSFECTION SYSTEMS - The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals. The present inventions also includes corresponding pharmaceutical preparations, especially for use in gene therapy as well as the use of such transfection agents as component in kits.09-11-2008
20130210149HUMAN G-PROTEIN CHEMOKINE RECEPTOR HSATU68 - Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.08-15-2013
20120252122METHODS AND COMPOSITIONS FOR INCREASING PRODUCTION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) - Disclosed herein are methods and compositions for increasing yield of induced pluripotent stem cells (iPSCs).10-04-2012
20080213899Rotationally Oscillating Injector - A microinjection device is provided that includes an injection element defining a longitudinal axis, and that further includes a motor. The injection element is rotatable about the longitudinal axis by the rotational motor. The injection element is for penetrating a target, such as a cell. A microinjection system is provided that includes the microinjection device and a control unit. The control unit is for controlling a rotational amplitude and a frequency of oscillation of the injection element. A method for penetrating a target to facilitate injecting material therein is provided that includes providing the material to an injection element, contacting the target with a distal end of the injection element, rotating the injection element about a longitudinal axis to form a hole in the target, and penetrating the target with the injection element via the hole formed in the target. A method for performing intra-cytoplasmic sperm injection is provided that includes providing a solution comprising sperm to an injection element, contacting an oocyte with a distal end of the injection element, rotating the injection element alternately clockwise and counterclockwise about a longitudinal axis to form a hole in the oocyte, penetrating the oocyte with the distal end of the injection element via the hole formed in the oocyte, and expelling the solution comprising sperm into the penetrated oocyte.09-04-2008
20110269234Methods and compositions for increasing nuclease activity - Disclosed herein are methods and compositions for increasing nuclease activity to increase nuclease-mediated genomic modifications.11-03-2011
20130102079POLYAMINE-CONTAINING POLYMERS AND METHODS OF SYNTHESIS AND USE - The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate).04-25-2013
20130102078NANOINJECTION SYSTEM DNA PLACEMENT PIPETTE COUPLER - Systems, devices, and methods for injecting biological material into a micro-object such as a cell are provided. In one aspect, for example, a cellular injection device can include a housing, an injection lance coupled to the housing and having a working tip extending outward from the housing, and a biological material delivery device coupled to the housing and having an effluent tip extending outward from the housing. The effluent tip can be positioned sufficiently proximal to the working tip such that biological material expelled from the effluent tip substantially contacts the working tip. In one aspect, the injection lance is removably coupled to the housing. In another aspect, the biological material delivery device is removably coupled to the housing.04-25-2013
20130102077ALTERATIONS UTILIZING NANOPARTICLES - Alterations utilizing nanoparticles. Certain embodiments of the invention are methods of delivering a substance to a target using a delivery-aid which includes nanoparticles. Those nanoparticles may be nanocarbon particles. Other embodiments are methods of delivering nanoparticles to a target involving placing a mask between a source of ballistic delivery of nanoparticles and the target. Other embodiments include irradiating a target to cause localized heating of the region of the target in which the nanodiamonds or OLC particles are present. Other embodiments utilize nanoparticles to make cells competent for genetic transformation. This abstract is not to be considered limiting, since other embodiments may deviate from the features described in this abstract.04-25-2013
20130115700METHOD FOR TRANSFECTING NUCLEIC ACID TO CELL AND NUCLEIC ACID COMPLEX - A method for transacting nucleic acid to cell comprising a step for forming a nucleic acid complex by bringing a double-stranded nucleic acid molecule into contact with a nucleic acid carrier having an amino acid sequence of alternating a basic amino acid and a hydrophobic amino acid, which has a peptide chain that forms a β-sheet structure in which a side chain of a positively charged basic amino acid is disposed on one surface side and a side chain of a hydrophobic amino acid is disposed on the opposite surface side in the presence of the double-stranded nucleic acid molecule having a double helix structure, and by binding the double-stranded nucleic acid molecule and the peptide chain through either one or both of the electrostatic interaction between the side chains of the basic amino acid and phosphate groups and hydrogen bonds between the double stranded-nucleic acid molecule and the peptide chain and a nucleic acid complex used for the same are disclosed.05-09-2013
20130122590AKT LIGANDS AND POLYNUCLEOTIDES ENCODING AKT LIGANDS - The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate AKT activity. The ligands, homopolyligands, and heteropolyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands, homopolyligands, and heteropolyligands.05-16-2013
20130130385SURFACE MARKERS AND USES THEREOF FOR RAPID STABLE CELL LINE GENERATION AND GENE AMPLIFICATION - The present invention provides methods of producing recombinant cells, methods of large scale production of a gene expression product (such as protein), and methods of establishing a stable cell line using the surface markers. Also provided are expression vectors encoding the surface markers and cells comprising the expression vectors. Further provided are gene expression products (such as proteins) and cells obtained using methods described herein, as well as kits useful for carrying out methods described herein.05-23-2013
20100279415LEPIDOPTERAN INSECT N-ACETYLGLUCOSAMINIDASE GENES AND THEIR USE IN GLYCOENGINEERING - A transgenic insect cell line for production of elevated levels of recombinant glycoproteins comprising mammalian-like N-glycans is provided. Also disclosed are nucleic acid sequences encoding β-N-acetylglucosaminidases.11-04-2010
20100279414INVENTION CONCERNING THE EXPRESSION AND PERMANENT RELEASE OF CANINE INTERLEUKINES - The present invention concerns the production, specific expression, and permanent release of canine interleukines, especially interleukin-2 (cIL-2) or interleukin-12 (cIL-12), from transfected BHK Tet-On cells, as well as the utilization of lymphokin-activated killer cells which were generated therewith for the tumor therapy in dogs.11-04-2010
20080199961ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS - The present disclosure relates to compounds and methods for inhibiting the formation of miRNAs that inhibit translation of one or more identified proteins. The compounds comprise antisense oligonucleotides targeting the pri-miRNA precursor of miRNAs.08-21-2008
20110223669METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS - The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells, comprising inhibiting the p53 function in the step of somatic cell nuclear reprogramming. The inhibition of p53 function is achieved by bringing a substance selected from the group consisting of (1) chemical inhibitors of p53, (2) dominant negative mutants of p53 and nucleic acids that encode the same, (3) siRNAs and shRNAs against p53 and DNAs that encode the same, and (4) p53 pathway inhibitors, into contact with a somatic cell, and the like. The present invention also provides an agent for improving the efficiency of establishment of iPS cells, the agent comprising an inhibitor of p53 function, particularly (1) chemical inhibitors of p53, (2) dominant negative mutants of p53 and nucleic acids that encode the same, (3) siRNAs and shRNAs against p53 and DNAs that encode the same, and (4) p53 pathway inhibitors. The present invention further provides a method of producing an iPS cell, comprising bringing a nuclear reprogramming substance and an inhibitor of p53 function into contact with a somatic cell.09-15-2011
20110236978REPROGRAMMING CELLS TOWARD A PLURIPOTENT STATE - The present invention relates to a process for preparing reprogrammed cells, in particular for preparing pluripotent and multipotent stem cells and to the pluripotent and multipotent stem cells prepared by said processes.09-29-2011
20110250693INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) - The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.10-13-2011
20130149785METHODS FOR MAKING AND USING MOLECULAR SWITCHES INVOLVING CIRCULAR PERMUTATION - The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.06-13-2013
20110275157COMPOSITION FOR REPROGRAMMING SOMATIC CELLS TO GENERATE INDUCED PLURIPOTENT STEM CELLS, COMPRISING Bmi1 AND LOW MOLECULAR WEIGHT SUBSTANCE, AND METHOD FOR GENERATING INDUCED PLURIPOTENT STEM CELLS USING THE SAME - Provided is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule encoding the Bmi1 protein; and b) at least one low molecular weight substance selected from the group consisting of a set of a MEK/ERK (mitogen-activated protein kinase/extracellular regulated kinase) inhibitor and a GSK (glycogen synthase kinase) inhibitor, a set of a G9a HMTase (G9a histone methyltransferase) inhibitor and a DMNT (DNA methyltransferase) inhibitor, and a histone deacetylase inhibitor. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the reprogramming factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.11-10-2011
20100291683Modified Antigen Presenting Cells and Methods of Use - The invention provides compositions comprising and methods of using antigen presenting cells into which has been introduced at least a first nucleotide sequence that encodes calnexin, wherein expression of calnexin in the antigen presenting cell increases the antigen presenting cell's ability to activate a T cell response.11-18-2010
20120258539USE OF NIBP POLYPEPTIDES - Methods for regulating NF-κB activation in cells comprising introducing into the cell a vector comprising a nucleic acid sequence encoding a NIK and IKK2 Binding Protein (NIBP) polypeptide, wherein the NIBP polypeptide is expressed in the cell, are provided. Also provided are methods for reversing the cancerous phenotype of a cancer cell and for modulating neuronal differentiation.10-11-2012
20100317114METHOD OF GENERATING GLUCOSE-RESPONSIVE CELLS - The present invention provides an improved method for generating cells. The method comprises differentiation of neuronal progenitor cells and transfecting of either already differentiated or progenitor cells to generate certain cells useful for the treatment of an illness such as diabetes.12-16-2010
20130183759METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS - The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells by inhibiting p38 function in the step of somatic cell nuclear reprogramming. The p38 function can be inhibited by bringing an inhibitor selected from the group consisting of (1) a chemical inhibitor of p38 (2) a dominant negative mutant of p38 or a nucleic acid that encodes the same, (3) a nucleic acid selected from the group consisting of siRNAs and shRNAs targeted to p38 and DNAs that encode the same and (4) an inhibitor of p38 pathway into contact with a somatic cell and the like. The present invention also provides an agent for improving the efficiency of establishment of induced pluripotent stem cells, which contains an inhibitor of p38 function, particularly an inhibitor selected from the group consisting of (1) a chemical inhibitor of p38 (2) a dominant negative mutant of p38 or a nucleic acid that encodes the same, (3) a nucleic acid selected from the group consisting of siRNAs and shRNAs targeted to p38 and DNAs that encode the same and (4) an inhibitor of p38 pathway. Moreover, the present invention provides a production method of iPS cells, which includes bringing a nuclear reprogramming substance and an inhibitor of p38 function into contact with a somatic cell.07-18-2013
20080280362Methods for reprogramming somatic cells - The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.11-13-2008
20120021522Method for the Evolutionary Design of Biochemical Reaction Networks - The present invention relates to methods for achieving an optimal function of a biochemical reaction network. The methods can be performed in silico using a reconstruction of a biochemical reaction network of a cell and iterative optimization procedures. The methods can further include laboratory culturing steps to confirm and possibly expand the determinations made using the in silico methods, and to produce a cultured cell, or population of cells, with optimal functions. The current invention includes computer systems and computer products including computer-readable program code for performing the in silico steps of the invention.01-26-2012
20120028357AAV VECTORS PRODUCED IN INSECT CELLS - The present invention relates to the production of adeno-associated viral vectors in insect cells. The insect cells therefore comprise a first nucleotide sequence encoding the adeno-associated virus (AAV) capsid proteins, whereby the initiation codon for translation of the AAV VP1 capsid protein is a non-ATG, suboptimal initiation codon. The insect cell further comprises a second nucleotide sequence comprising at least one AAV inverted terminal repeat (ITR) nucleotide sequence; a third nucleotide sequence comprising a Rep52 or a Rep40 coding sequence operably linked to expression control sequences for expression in an insect cell; and, a fourth nucleotide sequence comprising a Rep78 or a Rep68 coding sequence operably linked to expression control sequences for expression in an insect cell. The invention further relates to adeno-associated viral vectors with an altered ratio of the viral capsid proteins that provides improved infectivity of the viral particles.02-02-2012
20130095569PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2) POLYNUCLEOTIDES - The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.04-18-2013

Patent applications in class Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell

Patent applications in all subclasses Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell